<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Journal of Inherited Metabolic Disease via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Journal of Inherited Metabolic Disease' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Journal+of+Inherited+Metabolic+Disease&t=Journal+of+Inherited+Metabolic+Disease&s=Search&f=source]]></link>
        <lastBuildDate>Sun, 21 Mar 2010 16:41:18 +0100</lastBuildDate>
        <item>
            <title>Fatal cerebral edema associated with serine deficiency in CSF</title>
            <link>http://www.medworm.com/index.php?rid=3386679&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb522r0596x173235%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Two young girls without a notable medical history except for asthma presented with an acute toxic encephalopathy with very
 low serine concentrations both in plasma and cerebrospinal fluid (CSF) comparable to patients with 3-phosphoglycerate dehydrogenase
 (3-PGDH) deficiency. Clinical symptoms and enzyme measurement (in one patient) excluded 3-PGDH deficiency. Deficiencies in
 other serine biosynthesis enzymes were highly unlikely on clinical grounds. On basis of the fasting state, ketone bodies and
 lactate in plasma, urine and CSF, we speculate that reduced serine levels were due to its use as gluconeogenic substrate,
 conversion to pyruvate by brain serine racemase or decreased L-serine production because of a lack of glucose. These are the
 first strikingly similar...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386679</comments>
            <pubDate>Thu, 18 Mar 2010 19:38:43 +0100</pubDate>
            <guid isPermaLink="false">3386679</guid>        </item>
        <item>
            <title>Large neutral amino acids in daily practice</title>
            <link>http://www.medworm.com/index.php?rid=3386680&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3748x52775308584%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;At the Kennedy Centre for Phenylketonuria, Denmark, large neutral amino acids (LNAAs) are being used to treat adult and adolescent
 patients who are nonadherent to dietary treatment for phenylketonuria (PKU). At the start of treatment, a patient must undergo
 dietary analysis and regular blood sampling to measure plasma amino acid (AA) concentrations. The aim of this analysis and
 treatment is that the patient receives 25–30% of the daily protein requirement from LNAA supplementation and the remaining
 70–75% from natural, low-phenylalanine proteins (although some patients have difficulties in maintaining this level of protein
 intake). Patients are therefore able to follow a more “normal” diet than those adhering to a PKU diet with AA supplementation
 (in which...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386680</comments>
            <pubDate>Thu, 18 Mar 2010 19:38:37 +0100</pubDate>
            <guid isPermaLink="false">3386680</guid>        </item>
        <item>
            <title>Hydroxocobalamin for cobalamin C: which dosage?</title>
            <link>http://www.medworm.com/index.php?rid=3361710&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw580044x26306425%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s10545-010-9068-8Authors
		Viroj Wiwanitkit, Wiwanitkit House 38/167 Sukhapibarn 1 Road Bangkhae, Bangkok Thailand 10160
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3361710</comments>
            <pubDate>Thu, 11 Mar 2010 18:25:13 +0100</pubDate>
            <guid isPermaLink="false">3361710</guid>        </item>
        <item>
            <title>Profound biotinidase deficiency: a rare disease among native Swedes</title>
            <link>http://www.medworm.com/index.php?rid=3361711&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv2616k6533r72v6j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Biotinidase deficiency is an autosomal recessive metabolic disorder included in many newborn screening programmes. Prior to
 the introduction of screening for biotinidase deficiency in Sweden in 2002, the disorder was almost unknown, with only one
 case diagnosed clinically. Biotinidase activity was measured in dried blood spots with a semiquantitative method using biotin-6-amidoquinoline
 as substrate. The cutoff value was set at 25% (later lowered to 20%) of the mean activity of all samples measured on that
 day. The disorder was confirmed by quantitative determination of biotinidase activity in plasma and DNA analyses. Over a period
 of 6 years, 13 patients were identified among 637,452 screened newborns and 5,068 adoptive/immigrant children. None of the
 patients ha...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3361711</comments>
            <pubDate>Thu, 11 Mar 2010 18:25:10 +0100</pubDate>
            <guid isPermaLink="false">3361711</guid>        </item>
        <item>
            <title>Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment</title>
            <link>http://www.medworm.com/index.php?rid=3361714&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F733m025x2pk8l3kv%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Treatment with tetrahydrobiopterin (BH4), the natural cofactor of phenylalanine hydroxylase (PAH), can reduce blood phenylalanine (Phe) levels in patients with BH4-responsive phenylketonuria (PKU). A number of studies has reported on the short-term BH4 treatment of patients with PKU, but long-term data are lacking. Here, we describe the effects of long-term treatment with
 BH4 on 16 patients, who showed a &amp;gt;28% reduction in blood Phe following testing for BH4 overload. The mean dose of BH4 was 16&amp;nbsp;mg/kg body weight (range 5–36&amp;nbsp;mg/kg body weight). The mean treatment duration was 56&amp;nbsp;months (range 24–110&amp;nbsp;months).
 Of 16 patients, 14 achieved long-term Phe control with BH4 treatment, with a mean blood Phe concentration of 321 ± 236 µmol/l. T...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3361714</comments>
            <pubDate>Wed, 10 Mar 2010 18:33:33 +0100</pubDate>
            <guid isPermaLink="false">3361714</guid>        </item>
        <item>
            <title>Docosahexaenoic acid status in females of reproductive age with maple syrup urine disease</title>
            <link>http://www.medworm.com/index.php?rid=3361713&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F714l13j3w7516k63%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Individuals with maple syrup urine disease (MSUD) have impaired metabolism of branched-chain amino acids (BCAA) valine, isoleucine,
 and leucine. Life-long dietary therapy is recommended to restrict BCAA intake and thus prevent poor neurological outcomes
 and death. To maintain adequate nutritional status, the majority of protein and nutrients are derived from synthetic BCAA-free
 medical foods with variable fatty acid content. Given the restrictive diet and the importance of omega-3 fatty acids, particularly
 docosahexaenoic acid (DHA), in neurological development, this study evaluated the dietary and fatty acid status of females
 of reproductive age with MSUD attending a metabolic camp. Healthy controls of similar age and sex were selected from existing
 normal labora...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3361713</comments>
            <pubDate>Wed, 10 Mar 2010 18:33:33 +0100</pubDate>
            <guid isPermaLink="false">3361713</guid>        </item>
        <item>
            <title>Efficacy of recombinant human α-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients</title>
            <link>http://www.medworm.com/index.php?rid=3361712&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp311p5126t2w9257%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aims of the study were to assess the effectiveness of enzyme replacement therapy (ERT) with laronidase on the range of
 motion (ROM) of upper extremities and influence on activities of daily living (ADLs) of patients with mucopolysaccharidosis
 type&amp;nbsp;I (MPS&amp;nbsp;I). The ROM of 17 patients with MPS&amp;nbsp;I was followed from the first year of life until the introduction of ERT and
 after 52–208&amp;nbsp;weeks of treatment. In all patients (group&amp;nbsp;1, n = 10), passive ROM was assessed. In patients with Hurler/Scheie or Scheie phenotype (group&amp;nbsp;2, n = 7) both passive and active ROM, as well as daily life activities, were evaluated. Passive and active ROM was measured by
 a goniometer, while a health assessment questionnaire was used to assess activities ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3361712</comments>
            <pubDate>Wed, 10 Mar 2010 18:33:33 +0100</pubDate>
            <guid isPermaLink="false">3361712</guid>        </item>
        <item>
            <title>Newborn screening strategies for congenital hypothyroidism: an update</title>
            <link>http://www.medworm.com/index.php?rid=3330321&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn0t223124774389v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;It is the purpose of this article to briefly review the initial development and subsequent evolution of newborn screening
 programs to detect infants with congenital hypothyroidism (CH) and then to provide an update of the advantages and disadvantages
 of the main test strategies. Pilot programs began screening newborn populations in North America in the mid-1970s using either
 primary thyroxine (T4)-follow-up thyroid stimulating hormone (TSH) or primary TSH testing. Many programs in the United States
 and around the world continue to prefer a primary T4-follow-up TSH test strategy. This approach has the advantage of detecting
 infants with primary CH, as well as cases of hypopituitary hypothyroidism, by follow-up of infants with a T4 below an absolute
 cutoff or with a...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3330321</comments>
            <pubDate>Tue, 02 Mar 2010 10:06:17 +0100</pubDate>
            <guid isPermaLink="false">3330321</guid>        </item>
        <item>
            <title>A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation</title>
            <link>http://www.medworm.com/index.php?rid=3330320&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn5m65520229m7717%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Over the years, the mitochondrial fatty acid β-oxidation (FAO) pathway has been characterised at the biochemical level as
 well as the molecular biological level. FAO plays a pivotal role in energy homoeostasis, but it competes with glucose as the
 primary oxidative substrate. The mechanisms behind this so-called glucose–fatty acid cycle operate at the hormonal, transcriptional
 and biochemical levels. Inherited defects for most of the FAO enzymes have been identified and characterised and are currently
 included in neonatal screening programmes. Symptoms range from hypoketotic hypoglycaemia to skeletal and cardiac myopathies.
 The pathophysiology of these diseases is still not completely understood, hampering optimal treatment. Studies of patients
 and mouse models ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3330320</comments>
            <pubDate>Tue, 02 Mar 2010 10:06:17 +0100</pubDate>
            <guid isPermaLink="false">3330320</guid>        </item>
        <item>
            <title>Combined hyperlipidemia in patients with lysinuric protein intolerance</title>
            <link>http://www.medworm.com/index.php?rid=3305500&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe25277lx54778562%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Serum cholesterol and triglyceride values are markedly elevated in LPI patients. Although the mechanism of combined hyperlipidemia
 remains unknown and is not explained by fat consumption, hyperlipidemia is clearly progressive with age, suggesting that starting
 statin therapy early is probably beneficial. Statins are well-tolerated and efficacious in LPI.
 
 
 
 
	Content Type Journal ArticleCategory Research ReportDOI 10.1007/s10545-010-9050-5Authors
		Laura M. Tanner, University of Turku Department of Pediatrics Turku FinlandHarri Niinikoski, University of Turku Department of Pediatrics Turku FinlandKirsti Näntö-Salonen, University of Turku Department of Pediatrics Turku FinlandOlli Simell, University of Turku Department of Pediatrics Turku Finland
	

	
		Journal...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3305500</comments>
            <pubDate>Tue, 23 Feb 2010 08:10:54 +0100</pubDate>
            <guid isPermaLink="false">3305500</guid>        </item>
        <item>
            <title>Four years of expanded newborn screening in Portugal with tandem mass spectrometry</title>
            <link>http://www.medworm.com/index.php?rid=3305501&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F68732705661765k6%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Our data support the advantage of a centralised laboratory for screening an elevated number of samples and making decisions
 if relying on a clinical network able to provide fast treatment and a good outcome in the screened cases.
 
 
 
 
	Content Type Journal ArticleCategory Research ReportDOI 10.1007/s10545-010-9048-zAuthors
		Laura Vilarinho, Medical Genetics Center, National Institute of Health (INSA) Newborn Screening Unit Praca Pedro Nunes 88 4099-028 Porto PortugalHugo Rocha, Medical Genetics Center, National Institute of Health (INSA) Newborn Screening Unit Praca Pedro Nunes 88 4099-028 Porto PortugalCarmen Sousa, Medical Genetics Center, National Institute of Health (INSA) Newborn Screening Unit Praca Pedro Nunes 88 4099-028 Porto PortugalAna Marcão, Medica...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3305501</comments>
            <pubDate>Tue, 23 Feb 2010 08:10:51 +0100</pubDate>
            <guid isPermaLink="false">3305501</guid>        </item>
        <item>
            <title>Adenylosuccinate lyase deficiency in a Malaysian patient, with novel adenylosuccinate lyase gene mutations</title>
            <link>http://www.medworm.com/index.php?rid=3305503&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw706540567870314%2F</link>
            <description>We report on the first Malaysian case of ADSL deficiency, which appears also to be the first reported Asian case.
 The case was diagnosed among a cohort of 450 patients with clinical features of psychomotor retardation, global developmental
 delay, seizures, microcephaly and/or autistic behaviour. The patient presented with frequent convulsions and severe myoclonic
 jerk within the first few days of life and severe psychomotor retardation. The high performance liquid chromatography (HPLC)
 profile of the urine revealed the characteristic biochemical markers of succinyladenosine (S-Ado) and succinyl-aminoimidazole
 carboximide riboside (SAICAr). The urinary S-Ado/SAICAr ratio was found to be 1.02 (type&amp;nbsp;I ADSL deficiency). The patient was
 compound heterozygous for two novel mutations, ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3305503</comments>
            <pubDate>Tue, 23 Feb 2010 08:10:50 +0100</pubDate>
            <guid isPermaLink="false">3305503</guid>        </item>
        <item>
            <title>The risk of Parkinson’s disease in type 1 Gaucher disease</title>
            <link>http://www.medworm.com/index.php?rid=3305502&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm83864w41l229001%2F</link>
            <description>In conclusion, compared to the general population, patients with GD1 have an almost 20-fold
 increased life-time risk of developing PD.
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-010-9055-0Authors
		Gilberto Bultron, Yale University School of Medicine Department of Pediatrics and Internal Medicine 333 Cedar Street P.O. Box 208064 New Haven CT 06520-8064 USAKatherine Kacena, Yale University School of Medicine Department of Pediatrics and Internal Medicine 333 Cedar Street P.O. Box 208064 New Haven CT 06520-8064 USADaniel Pearson, Yale University School of Medicine Department of Pediatrics and Internal Medicine 333 Cedar Street P.O. Box 208064 New Haven CT 06520-8064 USAMichael Boxer, Arizona Hematology Oncology Tucson AZ USARuhua Yang, Yale University Sc...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3305502</comments>
            <pubDate>Tue, 23 Feb 2010 08:10:50 +0100</pubDate>
            <guid isPermaLink="false">3305502</guid>        </item>
        <item>
            <title>The effects of early and late bone marrow transplantation in siblings with alpha-mannosidosis. Is early haematopoietic cell transplantation the preferred treatment option?</title>
            <link>http://www.medworm.com/index.php?rid=3286619&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl1rukhk0204q3826%2F</link>
            <description>This article documents both the neurological and physical outcomes of the first published set of siblings undergoing transplantation
 at differing ages for α-mannosidosis. The older brother, the index case, was diagnosed at the age of 3&amp;nbsp;years and underwent
 transplantation at 13&amp;nbsp;years for the treatment of increasing somatic problems and recurrent infections. The younger brother
 had undergone transplantation pre-symptomatically at 6&amp;nbsp;months of age. Their clinical, radiological and developmental outcomes
 are documented and compared with the previous published cases, with the case for early transplantation being weighted against
 other potential therapies.
 
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s10545-009-9035-4Authors
		A. A. Broomfield, Royal Manch...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3286619</comments>
            <pubDate>Wed, 17 Feb 2010 18:32:17 +0100</pubDate>
            <guid isPermaLink="false">3286619</guid>        </item>
        <item>
            <title>The biochemical basis of hereditary fructose intolerance</title>
            <link>http://www.medworm.com/index.php?rid=3282678&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr51472j523n43771%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hereditary fructose intolerance is a rare, but potentially lethal, inherited disorder of fructose metabolism, caused by mutation
 of the aldolase B gene. Treatment currently relies solely on dietary restriction of problematic sugars. Biochemical study
 of defective aldolase B enzymes is key to revealing the molecular basis of the disease and providing a stronger basis for
 improved treatment and diagnosis. Such studies have revealed changes in enzyme activity, stability and oligomerisation. However,
 linking these changes to disease phenotypes has not always been straightforward. This review gives a general overview of the
 features of hereditary fructose intolerance, then concentrates on the biochemistry of the AP variant (Ala149Pro variant of
 aldolase B) and molecula...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282678</comments>
            <pubDate>Tue, 16 Feb 2010 18:09:37 +0100</pubDate>
            <guid isPermaLink="false">3282678</guid>        </item>
        <item>
            <title>Serum MIP-1 α level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice</title>
            <link>http://www.medworm.com/index.php?rid=3282679&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F95m4373543857508%2F</link>
            <description>In this study,
 we examined the effect of brain-directed lentiviral (LV) gene therapy on serum levels of macrophage inflammatory protein 1
 alpha (MIP-1α) and brain-derived neurotrophic factor (BDNF) proteins in the murine model of MPS IIIB to identify novel serum
 biomarkers. The cytokine MIP-1α was elevated in MPS IIIB mouse serum, and following gene therapy, it was reduced to normal
 levels. For neurotrophin BDNF, the difference in serum levels between MPS IIIB and normal mice was not statistically significant;
 after LV gene therapy, an increase in protein was found in treated mice, although the values were not statistically significant.
 Our studies suggest MIP-1α as the first serum biomarker that could be used to monitor disease progression and treatment for
 MPS IIIB disease.
 
 ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282679</comments>
            <pubDate>Tue, 16 Feb 2010 18:09:35 +0100</pubDate>
            <guid isPermaLink="false">3282679</guid>        </item>
        <item>
            <title>Therapeutic approaches for neuronopathic lysosomal storage disorders</title>
            <link>http://www.medworm.com/index.php?rid=3282680&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F102w5415g76j7p4q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Therapy of the central nervous system (CNS) manifestations of lysosomal storage diseases (LSDs) has remained a major challenge
 because of its inability to deliver therapeutic agents efficiently across the intact blood–brain barrier. Non-specific therapies
 such as hematopoietic stem cell transplantation have been useful in globoid cell leukodystrophy (Krabbe disease) and in some
 mucopolysaccharidoses. Anti-inflammatory agents also show promise as adjuvant therapy. High doses of replacement therapy with
 native or modified enzyme show renewed promise for correction of CNS cells. Alternatively, small molecules can enter the brain
 relatively easily and promote reduction of accumulated substrate or function as pharmacological chaperones to enhance the
 level of the def...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282680</comments>
            <pubDate>Tue, 16 Feb 2010 18:09:34 +0100</pubDate>
            <guid isPermaLink="false">3282680</guid>        </item>
        <item>
            <title>Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur</title>
            <link>http://www.medworm.com/index.php?rid=3282682&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg06230460n772212%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Synthesis of cysteine as a product of the transsulfuration pathway can be viewed as part of methionine or homocysteine degradation,
 with cysteine being the vehicle for sulfur conversion to end products (sulfate, taurine) that can be excreted in the urine.
 Transsulfuration is regulated by stimulation of cystathionine β-synthase and inhibition of methylene tetrahydrofolate reductase
 in response to changes in the level of S-adenosylmethionine, and this promotes homocysteine degradation when methionine availability
 is high. Cysteine is catabolized by several desulfuration reactions that release sulfur in a reduced oxidation state, generating
 sulfane sulfur or hydrogen sulfide (H2S), which can be further oxidized to sulfate. Cysteine desulfuration is accomplished by al...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282682</comments>
            <pubDate>Tue, 16 Feb 2010 18:09:33 +0100</pubDate>
            <guid isPermaLink="false">3282682</guid>        </item>
        <item>
            <title>Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I</title>
            <link>http://www.medworm.com/index.php?rid=3282681&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg166406t20813846%2F</link>
            <description>In conclusion, blood and urine
 levels of DS and HS provide an intrinsic monitoring and screening tool for MPS I patients.
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-9036-3Authors
		Shunji Tomatsu, Saint Louis University Department of Pediatrics St. Louis MO USAAdriana M. Montaño, Saint Louis University Department of Pediatrics St. Louis MO USAToshihiro Oguma, Daiichi-Sankyo Co., Ltd Tokyo JapanVu Chi Dung, Saint Louis University Department of Pediatrics St. Louis MO USAHirotaka Oikawa, Saint Louis University Department of Pediatrics St. Louis MO USATalita Giacomet de Carvalho, Saint Louis University Department of Pediatrics St. Louis MO USAMaría L. Gutiérrez, Saint Louis University Department of Pediatrics St. Louis MO USASeiji Yamaguchi, Shimane U...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282681</comments>
            <pubDate>Tue, 16 Feb 2010 18:09:33 +0100</pubDate>
            <guid isPermaLink="false">3282681</guid>        </item>
        <item>
            <title>The first case of mitochondrial acetoacetyl-CoA thiolase deficiency identified by expanded newborn metabolic screening in Italy: the importance of an integrated diagnostic approach</title>
            <link>http://www.medworm.com/index.php?rid=3282683&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqxv8612p7005q128%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A pilot expanded newborn screening programme to detect inherited metabolic disorders by means of liquid chromatography coupled
 with tandem mass spectrometry (LC-MS/MS) began in the Campania region, southern Italy, in 2007. By October 2009, &amp;gt;8,800 dried
 blood samples on filter paper from 11 hospitals had been screened. Within this screening programme, we identified a case of
 mitochondrial acetoacetyl-coenzyme A (CoA) thiolase deficiency [β-ketothiolase (β-KT) deficiency] by analysing the acylcarnitine
 profile from a dried blood spot with LC-MS/MS. Gas chromatography coupled with mass spectrometry analysis of urinary organic
 acids and LC-MS/MS analysis of urinary acylcarnitines were in line with this disorder. In fact, concentrations were well beyond
 the cut-of...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282683</comments>
            <pubDate>Tue, 16 Feb 2010 06:42:05 +0100</pubDate>
            <guid isPermaLink="false">3282683</guid>        </item>
        <item>
            <title>Chorionic villi ultrastructure in the prenatal diagnosis of glycogenosis type II</title>
            <link>http://www.medworm.com/index.php?rid=3282684&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F078687253388156v%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Ultrastructural findings correlated with biochemical and genetic results, providing a clear and early indicator of the definite
 diagnosis for future pregnancy management or an early therapeutic approach.
 
 
 
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s10545-009-9033-6Authors
		Beatriz San Millan, University Hospital of Vigo, Meixoeiro Department of Pathology and Neuropathology Vigo 36200 SpainSusana Teijeira, University Hospital of Vigo, Meixoeiro Department of Pathology and Neuropathology Vigo 36200 SpainCarmen Domínguez, Hospital Universitari Vall d’Hebron, Centre for Biomedical Research on Rare Diseases (CIBERER) Biochemistry and Molecular Biology Research Center Barcelona SpainIrene Vieitez, University Hospital of Vigo, Meixoeiro Departm...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3282684</comments>
            <pubDate>Tue, 16 Feb 2010 06:42:03 +0100</pubDate>
            <guid isPermaLink="false">3282684</guid>        </item>
        <item>
            <title>Biochemical abnormalities in a patient with thymidine phosphorylase deficiency with fatal outcome</title>
            <link>http://www.medworm.com/index.php?rid=3270846&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fml08h27466360715%2F</link>
            <description>This report shows that TP deficiency
 is a severe clinical condition with a broad spectrum of affected tissues. TP deficiency can be easily determined by the measurement
 of pyrimidine metabolites in body fluids and TP activity in peripheral blood leucocytes. Early detection and treatment may
 prevent the progress of the clinical symptoms and, therefore, should be considered for inclusion in newborn screening programmes.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s10545-010-9049-yAuthors
		Jaap A. Bakker, Maastricht University Medical Centre Department of Clinical Genetics, Laboratory for Biochemical Genetics P. Debyelaan 25 6229 HX Maastricht The NetherlandsPatrick Schlesser, CHC Clinique de l’Espérance Department of Paediatrics Montegnée-Liege BelgiumHubert J. M. ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270846</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:42 +0100</pubDate>
            <guid isPermaLink="false">3270846</guid>        </item>
        <item>
            <title>Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle</title>
            <link>http://www.medworm.com/index.php?rid=3270847&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F54645v321522n562%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Current therapy for phenylketonuria (PKU) consists of life-long dietary restriction of phenylalanine (Phe), which presents
 problems of adherence for patients. Alternative therapies under investigation include, among others, the use of gene therapy
 to provide copies of wild-type, non-mutant, phenylalanine hydroxylase (PAH) enzyme. Expression of PAH in both liver (the usual
 metabolic source of this enzyme) and skeletal muscle is under investigation. Liver gene therapy, using a viral vector based
 on the adeno-associated viruses (AAVs), provided effective clearance of serum Phe that was sustained for 1&amp;nbsp;year in some mice.
 In order for PAH expression to be effective in skeletal muscle, the essential metabolic cofactor, tetrahydrobiopterin (BH4), must also be provide...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270847</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:40 +0100</pubDate>
            <guid isPermaLink="false">3270847</guid>        </item>
        <item>
            <title>Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites</title>
            <link>http://www.medworm.com/index.php?rid=3270848&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl02p17ru5v820160%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Phenylketonuria (PKU) is a metabolic genetic disease characterized by deficient phenylalanine hydroxylase (PAH) enzymatic
 activity. Brain hypomyelination has been reported in untreated patients, but its mechanism remains unclear. We therefore investigated
 the influence of phenylalanine (Phe), phenylpyruvate (PP), and phenylacetate (PA) on oligodendrocytes. We fisrt showed in
 a mouse model of PKU that the number of oligodendrocytes is not different in corpus callosum sections from adult mutants or
 from control brains. Then, using enriched oligodendroglial cultures, we detected no cytotoxic effect of high concentrations
 of Phe, PP, or PA. Finally, we analyzed the impact of Phe, PP, and PA on the myelination process in myelinating cocultures
 using both an in vitro in...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270848</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:38 +0100</pubDate>
            <guid isPermaLink="false">3270848</guid>        </item>
        <item>
            <title>Disease mechanisms and protein structures in fatty acid oxidation defects</title>
            <link>http://www.medworm.com/index.php?rid=3270850&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2v216132187g1uh8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In fatty acid oxidation defects, the majority of gene variations are of the missense type and, therefore, prone to inducing
 misfolding in the resulting mutant protein. The fate of the mutant protein depends on the nature of the gene variation and
 other genetic factors as well as cellular and environmental factors. Since it has been shown that certain fatty acid oxidation
 enzyme proteins, exemplified by mutant medium-chain and short-chain acyl-CoA dehydrogenases as well as electron transfer flavoprotein
 and electron transfer flavoprotein dehydrogenase, may accumulate during cellular stress, e.g. elevated temperature, there
 is speculation about how such proteins may disturb the integrity of the putative fatty acid oxidation metabolone, in which
 the two flavoproteins...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270850</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:35 +0100</pubDate>
            <guid isPermaLink="false">3270850</guid>        </item>
        <item>
            <title>Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis</title>
            <link>http://www.medworm.com/index.php?rid=3270849&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2777286134785865%2F</link>
            <description>In conclusion, we present a reliable diagnostic system to verify an FBPase deficiency and find
 the genetic aberration.
 
	Content Type Journal ArticleCategory Research ReportDOI 10.1007/s10545-009-9034-5Authors
		Cristine Åsberg, Sahlgrenska University Hospital Department of Clinical Chemistry and Transfusion Medicine 41345 Gothenburg SwedenOla Hjalmarson, University of Gothenburg Department of Paediatrics, Children’s Hospital Gothenburg SwedenJan Alm, Karolinska University Hospital Astrid Lindgrens Children’s Hospital Stockholm SwedenTommy Martinsson, University of Gothenburg Department of Clinical Genetics Gothenburg SwedenJohan Waldenström, Sahlgrenska University Hospital Department of Clinical Chemistry and Transfusion Medicine 41345 Gothenburg SwedenChristina Hellerud, Sahlgren...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270849</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:35 +0100</pubDate>
            <guid isPermaLink="false">3270849</guid>        </item>
        <item>
            <title>Nutritional issues in treating phenylketonuria</title>
            <link>http://www.medworm.com/index.php?rid=3270851&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh510716801855w16%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A phenylalanine (Phe)-restricted diet is the mainstay of phenylketonuria (PKU) treatment, and, in recent years, the nutritional
 management of PKU has become more complex in order to optimize patients’ growth, development and diet compliance. Dietary
 restriction of Phe creates a diet similar to a vegan diet, and many of the nutritional concerns and questions applicable to
 vegans who wish to avoid animal products are also relevant to patients with PKU. Owing to their nutritional characteristics,
 breast milk and breastfeeding should be given greater consideration as a useful food in patients with PKU and in those with
 other inborn errors of metabolism. Further key issues for consideration include the quality of the available amino acid substitutes,
 the neurotrophic...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270851</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:34 +0100</pubDate>
            <guid isPermaLink="false">3270851</guid>        </item>
        <item>
            <title>Diet and visually significant cataracts in galactosaemia: is regular follow up necessary?</title>
            <link>http://www.medworm.com/index.php?rid=3270852&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1240u281761x6775%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Cataracts affecting vision were not found in our cohort. A direct relationship between dietary compliance and cataract formation
 was not demonstrated. On the basis of our data, regular life-long ophthalmic exam of patients with classic galactosemia seems
 to be unnecessary.
 
 
 
 Take-home message&amp;nbsp;&amp;nbsp;Cataracts which develop in patients with classical Galactosaemia do not usually affect vision and may be unrelated to compliance
 to diet.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-9042-5Authors
		John Widger, Children’s University Hospital The National Centre for Inherited Metabolic Disorders Dublin IrelandJennifer O’Toole, Children’s University Hospital The National Centre for Inherited Metabolic Disorders Dublin ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270852</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:33 +0100</pubDate>
            <guid isPermaLink="false">3270852</guid>        </item>
        <item>
            <title>Classical galactosemia in Estonia: selective neonatal screening, incidence, and genotype/phenotype data of diagnosed patients</title>
            <link>http://www.medworm.com/index.php?rid=3270853&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp5882k64w8q67374%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s10545-010-9045-2Authors
		Katrin Õunap, Tartu University Hospital Department of Genetics, United Laboratories 2 Puusepa Street Tartu 51014 EstoniaKairit Joost, University of Tartu The Centre of Excellence for Translational Medicine Tartu EstoniaTriinu Temberg, Asper Biotech Tartu EstoniaKülliki Krabbi, Central Laboratory of Health Protection Inspectorate Tallinn EstoniaNeeme Tõnisson, Tartu University Hospital Department of Genetics, United Laboratories 2 Puusepa Street Tartu 51014 Estonia
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270853</comments>
            <pubDate>Fri, 12 Feb 2010 07:14:30 +0100</pubDate>
            <guid isPermaLink="false">3270853</guid>        </item>
        <item>
            <title>Erratum to: Long-term exposure of human proximal tubule cells to hydroxycobalamin[c-lactam] as a possible model to study renal disease in methylmalonic acidurias</title>
            <link>http://www.medworm.com/index.php?rid=3270854&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmj1q852g46321178%2F</link>
            <description>Content Type Journal ArticleCategory ErratumDOI 10.1007/s10545-010-9064-zAuthors
		S. W. Sauer, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 153 69120 Heidelberg GermanyS. Opp, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 153 69120 Heidelberg GermanyA. Haarmann, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 153 69120 Heidelberg GermanyJ. G. Okun, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 153 69120 Heidelberg GermanyS. Kölker, U...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270854</comments>
            <pubDate>Thu, 11 Feb 2010 11:39:25 +0100</pubDate>
            <guid isPermaLink="false">3270854</guid>        </item>
        <item>
            <title>Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase</title>
            <link>http://www.medworm.com/index.php?rid=3248398&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5840068768m62676%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pulmonary function is impaired in untreated mucopolysaccharidosis type VI (MPS VI). Pulmonary function was studied in patients
 during long-term enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB; rhN-acetylgalactosamine 4-sulfatase). Pulmonary function tests prior to and for up to 240&amp;nbsp;weeks of weekly infusions of rhASB
 at 1&amp;nbsp;mg/kg were completed in 56 patients during Phase 1/2, Phase 2, Phase 3 and Phase 3 Extension trials of rhASB and the
 Survey Study. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and, in a subset of patients, maximum voluntary
 ventilation (MVV), were analyzed as absolute volume in liters. FEV1 and FVC showed little change from baseline during the
 first 24&amp;nbsp;weeks of ERT, but after 96&amp;n...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3248398</comments>
            <pubDate>Fri, 05 Feb 2010 18:18:08 +0100</pubDate>
            <guid isPermaLink="false">3248398</guid>        </item>
        <item>
            <title>An overview of a cohort of South African patients with mitochondrial disorders</title>
            <link>http://www.medworm.com/index.php?rid=3248399&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3u846q2552272278%2F</link>
            <description>The objective of this paper is to describe the profile of patients with
 mitochondrial disorders in South Africa. Patients with possible mitochondrial disorders were accessed over 10 years. Analyses
 for respiratory chain and pyruvate dehydrogenase complex enzymes were performed on muscle. A diagnosis of a mitochondrial
 disorder was accepted only if an enzyme activity was deficient. Sixty-three patients were diagnosed with a mitochondrial disorder,
 including 40 African, 20 Caucasian, one mixed ancestry, and two Indian patients. The most important findings were the difference
 between African patients and other ethnicities: respiratory chain enzyme complexes CI+III or CII+III deficiencies were found
 in 52.5% of African patients, being of statistical significance (p value = 0.0061). T...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3248399</comments>
            <pubDate>Fri, 05 Feb 2010 07:57:38 +0100</pubDate>
            <guid isPermaLink="false">3248399</guid>        </item>
        <item>
            <title>A novel mutation in LMBRD1 causes the cblF defect of vitamin B12 metabolism in a Turkish patient</title>
            <link>http://www.medworm.com/index.php?rid=3242669&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2433j665348k3077%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the cblF defect of vitamin B12 (cobalamin) metabolism, cobalamin is trapped in lysosomes. Consequently, cobalamin coenzyme synthesis is blocked, and cofactors
 for methionine synthase and methylmalonyl-coenzyme A (CoA) mutase are deficient. We recently identified LMBRD1 as the causative gene located on chromosome 6q13 and showed that 18 out of 24 alleles in unrelated patients carried the deletion
 c.1056delG (p.L352fsX18) (Rutsch et al. (Nat Genet 41:234–239, 2009). LMBRD1 encodes the lysosomal membrane protein LMBD1, which presumably facilitates lysosomal cobalamin export. Our patient is the
 second child of consanguineous Turkish parents. He presented on the second day of life with cerebral seizures due to intraventricular
 hemorrhage. Plasma homocysteine and uri...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3242669</comments>
            <pubDate>Tue, 02 Feb 2010 17:52:29 +0100</pubDate>
            <guid isPermaLink="false">3242669</guid>        </item>
        <item>
            <title>A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=3234599&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg4m5333881061j17%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;EGP was severely hampered in both patients, resulting in hypoglycemia. However, despite defective hepatic and renal GNG in
 both disorders and defective hepatic GGL in GSD-1a, both patients were still able to produce glucose via both pathways. As
 all necessary enzymes of these pathways have now been functionally detected in muscle, a contribution of muscle to EGP during
 fasting via both GGL as well as GNG is suggested.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-9030-9Authors
		Hidde H. Huidekoper, University Hospital of Amsterdam Department of Pediatrics (G8-205) Academic Medical Center PO Box 22660 NL-1100 DD Amsterdam The NetherlandsGepke Visser, University Medical Center Utrecht Wilhelmina Children’s Hospital Utrecht The...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3234599</comments>
            <pubDate>Mon, 01 Feb 2010 18:07:41 +0100</pubDate>
            <guid isPermaLink="false">3234599</guid>        </item>
        <item>
            <title>PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease</title>
            <link>http://www.medworm.com/index.php?rid=3224643&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa75n868374632604%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Screening of blood films for the presence of periodic acid-Schiff (PAS)-positive lymphocyte vacuoles is sometimes used to
 support the diagnosis of Pompe disease, but the actual diagnostic value is still unknown. We collected peripheral blood films
 from 65 untreated Pompe patients and 51 controls. Lymphocyte vacuolization was quantified using three methods: percentage
 vacuolated lymphocytes, percentage PAS-positive lymphocytes, and a PAS score depending on staining intensity. Diagnostic accuracy
 of the tests was assessed using receiver operating characteristic (ROC) curves. All three methods fully discerned classic
 infantile patients from controls. The mean values of patients with milder forms of Pompe disease were significantly higher
 than those of controls, but f...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224643</comments>
            <pubDate>Wed, 27 Jan 2010 19:55:44 +0100</pubDate>
            <guid isPermaLink="false">3224643</guid>        </item>
        <item>
            <title>Mouse models for nuclear DNA-encoded mitochondrial complex I deficiency</title>
            <link>http://www.medworm.com/index.php?rid=3224645&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqv11520243p5r837%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mitochondrial diseases are a group of heterogeneous pathologies with decreased cellular energy production as a common denominator.
 Defects in the oxidative phosphorylation (OXPHOS) system, the most frequent one in humans being isolated complex&amp;nbsp;I deficiency
 (OMIM 252010), underlie this disturbed-energy generation. As biogenesis of OXPHOS complexes is under dual genetic control,
 with complex&amp;nbsp;II being the sole exception, mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) are found. Increasing
 knowledge is becoming available with respect to the pathophysiology and cellular consequences of OXPHOS dysfunction. This
 aids the rational design of new treatment strategies. Recently, the first successful treatment trials were carried out in
 patient-d...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224645</comments>
            <pubDate>Wed, 27 Jan 2010 19:55:41 +0100</pubDate>
            <guid isPermaLink="false">3224645</guid>        </item>
        <item>
            <title>Genotype–phenotype correlations: sudden death in an infant with very-long-chain acyl-CoA dehydrogenase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=3224644&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9035743757473891%2F</link>
            <description>We present a patient who died as a result of fatal hypoglycemia at 38 h of life before diagnosis of VLCADD
 could be established by newborn screening. Despite the early onset of the disease, the patient was found to have a missense
 mutation within the ACADVL gene with a c.848T&amp;gt;C, c.342+1G&amp;gt;C genotype. Genotype alone remains limited in its predictive ability to determine which affected
 individuals are at risk for fatal complications.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s10545-009-9041-6Authors
		Curtis R. Coughlin, Section of Biochemical Genetics, The Children’s Hospital of Philadelphia 34th&amp; Civic blvd. 9S23 Philadelphia PA 19104 USACan Ficicioglu, Section of Biochemical Genetics, The Children’s Hospital of Philadelphia 34th&amp; Civic blvd. 9S23 Philadelp...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224644</comments>
            <pubDate>Wed, 27 Jan 2010 19:55:41 +0100</pubDate>
            <guid isPermaLink="false">3224644</guid>        </item>
        <item>
            <title>Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography–tandem mass spectrometry</title>
            <link>http://www.medworm.com/index.php?rid=3224646&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg173w6066297671w%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mucopolysaccharidosis type&amp;nbsp;IVA (MPS IVA, Morquio&amp;nbsp;A disease), a progressive lysosomal storage disease, causes skeletal chondrodysplasia
 through excessive storage of keratan sulfate (KS). KS is synthesized mainly in cartilage and released to the circulation.
 The excess storage of KS disrupts cartilage, consequently releasing more KS into circulation, which is a critical biomarker
 for MPS IVA. Thus, assessment of KS level provides a potential screening strategy and determines clinical course and efficacy
 of therapies. We have recently developed a tandem mass spectrometry liquid chromatography [LC/MS/MS] method to assay KS levels
 in blood. Forty-nine blood specimens from patients with MPS IVA [severe (n = 33), attenuated (n = 11) and undefined (n =...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224646</comments>
            <pubDate>Wed, 27 Jan 2010 19:55:40 +0100</pubDate>
            <guid isPermaLink="false">3224646</guid>        </item>
        <item>
            <title>Social-adaptive and psychological functioning of patients affected by Fabry disease</title>
            <link>http://www.medworm.com/index.php?rid=3196633&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj537507152736071%2F</link>
            <description>This study shows for the first time that FD patients,
 particularly women, are affected by decreased social-adaptive functioning. Comprehensive treatment plans for FD should consider
 assessments and interventions to evaluate and improve social, occupational, and psychological functioning. Attention to the
 behavioral aspects of FD could lead to improved treatment outcome and improved quality of life. Individuals affected by Fabry
 disease exhibited social-adaptive functioning deficits that were significantly correlated with anxiety, depression, antisocial
 behavior, and AD/H problems in a sampling of our male and female patients aged between 18&amp;nbsp;years and 59&amp;nbsp;years.
 
	Content Type Journal ArticleCategory Research ReportDOI 10.1007/s10545-009-9025-6Authors
		Dawn Alyssia Laney, Em...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3196633</comments>
            <pubDate>Tue, 19 Jan 2010 17:46:21 +0100</pubDate>
            <guid isPermaLink="false">3196633</guid>        </item>
        <item>
            <title>Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry</title>
            <link>http://www.medworm.com/index.php?rid=3192529&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7521678128810723%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Neurological manifestations of GD often begin to appear before the age of 2&amp;nbsp;years. The most common neurological signs and
 manifestations are brainstem abnormalities and fine motor dysfunction. The most common genotype is L444P/L444P.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-9009-6Authors
		Anna Tylki-Szymańska, The Children’s Memorial Health Institute Clinic of Metabolic Diseases, Endocrinology and Diabetology Al. Dzieci Polskich 20 04 736 Warsaw PolandAshok Vellodi, Great Ormond Street Children’s Hospital NHS Trust London UKAmal El-Beshlawy, Pediatric Hospital of Cairo University Cairo EgyptJ. Alexander Cole, Biostatistics/Epidemiology, Biomedical Data Sciences and Informatics, Genzyme Corporation Cambridge MA USA...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3192529</comments>
            <pubDate>Mon, 18 Jan 2010 18:49:31 +0100</pubDate>
            <guid isPermaLink="false">3192529</guid>        </item>
        <item>
            <title>Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones</title>
            <link>http://www.medworm.com/index.php?rid=3192530&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn93637247l11j2nl%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mucopolysaccharidoses are autosomal and recessive lysosomal storage disorders caused by the deficiency of a lysosomal enzyme
 involved in glycosaminoglycan catabolism. The Sanfilippo type A disease (MPS III A) results from sulfamidase deficiency, which
 leads to accumulation of heparan sulfate, whereas Sly disease (MPS VII) results from beta-glucuronidase deficiency, leading
 to accumulation of heparan, dermatan, and chondroitin sulfates. These syndromes are characterized by severe central nervous
 system degeneration, resulting in progressive mental retardation, and fatality occurs in severely affected children. To date,
 no effective treatment is available except for bone marrow transplantation in specific cases. Recently, the use of genistein,
 an isoflavone that inh...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3192530</comments>
            <pubDate>Mon, 18 Jan 2010 18:49:29 +0100</pubDate>
            <guid isPermaLink="false">3192530</guid>        </item>
        <item>
            <title>Aberrant synthesis of ATP synthase resulting from a novel deletion in mitochondrial DNA in an African patient with progressive external ophthalmoplegia</title>
            <link>http://www.medworm.com/index.php?rid=3192531&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp601177mm2t28661%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A young, adult, African male patient presented with progressive proximal muscle weakness, external ophthalmoplegia and ptosis,
 as well as cardiac conduction abnormalities resembling Kearns–Sayre syndrome (KSS). Magnetic resonance imaging (MRI) of the
 brain revealed normal basal ganglia but bilateral well-circumscribed lesions in the cerebellar peduncles. Enzyme deficiencies
 in oxidative phosphorylation (OXPHOS) complexes I, IV and V was measured in muscle tissue. Blue native polyacrylamide gel
 electrophoresis (BN-PAGE) confirmed decreased protein content and activity of these complexes and revealed the presence of
 two catalytically active complex V sub-complexes. Upon investigation by molecular genetics, the mitochondrial DNA (mtDNA)
 copy number was found to be ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3192531</comments>
            <pubDate>Fri, 15 Jan 2010 18:02:35 +0100</pubDate>
            <guid isPermaLink="false">3192531</guid>        </item>
        <item>
            <title>Xanthine dehydrogenase deficiency with novel sequence variations presenting as rheumatoid arthritis in a 78-year-old patient</title>
            <link>http://www.medworm.com/index.php?rid=3192532&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F14326u188386555r%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Hereditary xanthinuria is a rare disorder, but it also needs to be considered in patients not originating from Mediterranean
 countries or the Near or Middle East. Urate concentration in serum and urine may provide an initial indication of XDH deficiency
 before high-performance liquid chromatography (HPLC) analysis is performed. The key to identifying the disorder is a greater
 awareness of XDH deficiency amongst primary care physicians, nephrologists, and urologists, but also rheumatologists. The
 diagnosis and therapeutic management requires a multidisciplinary approach.
 
 
 
	Content Type Journal ArticleCategory Research ReportDOI 10.1007/s10545-009-9011-zAuthors
		Agnieszka Jurecka, The Children’s Memorial Health Institute Department of Metabolic Diseases, End...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3192532</comments>
            <pubDate>Fri, 15 Jan 2010 00:45:49 +0100</pubDate>
            <guid isPermaLink="false">3192532</guid>        </item>
        <item>
            <title>Post-ictal psychosis in adolescent Niemann-Pick disease type C</title>
            <link>http://www.medworm.com/index.php?rid=3178057&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F50p1gx106x668040%2F</link>
            <description>We describe the presentation of an adolescent with juvenile-onset Niemann-Pick disease type C (NPC) who presented with post-ictal
 psychosis in the context of a developing seizure disorder. After demonstrating mild gait disturbance beginning at the age
 of 4 years, he was diagnosed with NPC at age 12 on the basis of 95% of cultured fibroblasts staining positive for filipin
 and a reduced fibroblast cholesterol esterification rate. He then developed a seizure disorder at age 15, where clusters of
 seizures produced typical psychotic symptoms, including hallucinations and delusions. His seizure disorder responded to valproate,
 which resulted in a settling of his psychotic symptoms. Whilst post-ictal psychosis is rarely reported prior to the age of
 16, NPC in adolescents and adults is parti...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3178057</comments>
            <pubDate>Wed, 13 Jan 2010 06:45:48 +0100</pubDate>
            <guid isPermaLink="false">3178057</guid>        </item>
        <item>
            <title>Clinical and biochemical monitoring of patients with fatty acid oxidation disorders</title>
            <link>http://www.medworm.com/index.php?rid=3170397&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft56746v35426r539%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Evidence-based guidelines for monitoring patients with disorders in fatty acid oxidation (FAO) are lacking, and most protocols
 are based on expert statements. Here, we describe our protocol for Danish patients. Clinical monitoring is the most important
 measure and has the main aims of checking growth, development and diet and of bringing families to the clinic regularly to
 remind them of their child’s risk and review how they cope and adjust, e.g. to an acute intercurrent illness. Most of these
 measures are simple and can be carried out during a routine out-patient visit; we seldom do more complicated assessments by
 a neuropsychologist, speech therapist, or physical and occupational therapists. Paraclinical measurements are not used for
 short-chain and medium-ch...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3170397</comments>
            <pubDate>Mon, 11 Jan 2010 18:22:53 +0100</pubDate>
            <guid isPermaLink="false">3170397</guid>        </item>
        <item>
            <title>Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation</title>
            <link>http://www.medworm.com/index.php?rid=3162803&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhwr903j7u962vh40%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Phenylketonuria (PKU) is an inherited metabolic disease characterized by phenylalanine (Phe) accumulation due to defects in
 the enzyme phenylalanine hydroxylase (PAH). Phe accumulation can lead to cognitive impairment. Some individuals with PKU respond
 to tetrahydrobiopterin (BH4) treatment, the natural cofactor of PAH, by a reduction in blood Phe concentrations. We tested
 12 patients with PKU, 8–29&amp;nbsp;years of age, all carrying the common Y414C mutation in the PAH gene. Three were homozygous and nine were compound heterozygous, with the second mutation being a putative null mutation.
 During the study period, genuine protein was increased to approximately 1&amp;nbsp;g/kg. The patients were treated with 20, 10, and
 5&amp;nbsp;mg BH4/kg/day for 1 week on each dose, start...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3162803</comments>
            <pubDate>Fri, 08 Jan 2010 21:40:50 +0100</pubDate>
            <guid isPermaLink="false">3162803</guid>        </item>
        <item>
            <title>Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder</title>
            <link>http://www.medworm.com/index.php?rid=3162804&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe6hv606595526740%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Glycogen storage disease type IV (GSD IV; Andersen disease) is caused by a deficiency of glycogen branching enzyme (GBE),
 leading to excessive deposition of structurally abnormal, amylopectin-like glycogen in affected tissues. The accumulated glycogen
 lacks multiple branch points and thus has longer outer branches and poor solubility, causing irreversible tissue and organ
 damage. Although classic GSD IV presents with early onset of hepatosplenomegaly with progressive liver cirrhosis, GSD IV exhibits
 extensive clinical heterogeneity with respect to age at onset and variability in pattern and extent of organ and tissue involvement.
 With the advent of cloning and determination of the genomic structure of the human GBE gene (GBE1), molecular analysis and characterizati...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3162804</comments>
            <pubDate>Thu, 07 Jan 2010 22:23:27 +0100</pubDate>
            <guid isPermaLink="false">3162804</guid>        </item>
        <item>
            <title>A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy</title>
            <link>http://www.medworm.com/index.php?rid=3155435&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F47330775385n7g82%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Our results suggest that excessive prenatal GABA exposure in the central nervous system (CNS) was responsible for the clinical
 manifestations of GABA transaminase deficiency. Our findings suggest the dual nature of GABA as an excitatory molecule early
 in life, followed by a functional switch to an inhibitory species later in development. Furthermore, quantitative 1H-MRS appears to be a useful, noninvasive tool for detecting inborn errors of GABA metabolism in the CNS.
 
 
 
	Content Type Journal ArticleCategory Rapid CommunicationDOI 10.1007/s10545-009-9022-9Authors
		Megumi Tsuji, Kanagawa Children’s Medical Center Division of Neurology, Clinical Research Institute 2-138-4 Mutsukawa, Minami-ku Yokohama 232-8555 JapanNoriko Aida, Kanagawa Children’s Medical Cen...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155435</comments>
            <pubDate>Tue, 05 Jan 2010 17:02:01 +0100</pubDate>
            <guid isPermaLink="false">3155435</guid>        </item>
        <item>
            <title>The monitoring of trace elements in blood samples from patients with inborn errors of metabolism</title>
            <link>http://www.medworm.com/index.php?rid=3155436&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb01k52m8v377u520%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients having inborn errors of intermediary metabolism (IEMs) may have element deficiencies related to dietary treatment.
 Our objective was to study several elements [cobalt (Co), copper (Cu), zinc (Zn), selenium (Se), manganese (Mn), molybdenum
 (Mo) and magnesium (Mg)] in patients with IEMs with and without dietary treatment and to compare these results with those
 established in a healthy paediatric population. We studied 72 patients with IEMs (age range 2&amp;nbsp;months–44&amp;nbsp;years; median 10.5&amp;nbsp;years),
 with and without protein-restricted dietary treatment. Control values were established in 92 subjects (age range 1&amp;nbsp;day–42&amp;nbsp;years;
 median 6.5&amp;nbsp;years). Dietary treatment consisted of a natural protein-restricted diet supplemented with a special...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155436</comments>
            <pubDate>Tue, 05 Jan 2010 17:01:59 +0100</pubDate>
            <guid isPermaLink="false">3155436</guid>        </item>
        <item>
            <title>Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution</title>
            <link>http://www.medworm.com/index.php?rid=3155437&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ftn3600w368437854%2F</link>
            <description>We present an 11-year-old girl affected by the severe
 form of MPS-II who was followed up over a time span of 8&amp;nbsp;years, focusing on clinical and brain MRI evolution. In the last
 2.5&amp;nbsp;years, the patient has been treated with enzyme replacement therapy (ERT) with idursulfase (Elaprase™, Shire Human Genetic
 Therapies AB, Sweden). On brain and cervical MRI examination, abnormalities in our patient did not differ from those detected
 in male patients: J-shaped pituitary sella, enlargement of perivascular spaces, brain atrophy, mild T2-hyperintensity in the
 paratrigonal white matter, diffuse platyspondylia, and mild odontoid dysplasia with odontoid cup. Brain atrophy progressed
 despite ERT introduction, whereas perivascular space enlargement did not change significantly before and ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155437</comments>
            <pubDate>Tue, 05 Jan 2010 17:01:58 +0100</pubDate>
            <guid isPermaLink="false">3155437</guid>        </item>
        <item>
            <title>Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5′-phosphate availability</title>
            <link>http://www.medworm.com/index.php?rid=3155438&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw4054u6227r05573%2F</link>
            <description>We describe two neonates presenting with perinatal hypophosphatasia and severe epileptic encephalopathy resulting in death.
 Both had increased levels of urinary vanillactate, indicating functional deficiency of aromatic amino acid decarboxylase,
 a pyridoxal-5-phosphate (PLP)-dependent enzyme required for dopamine and serotonin biosynthesis. Clinical findings and results
 of subsequent metabolic investigations were consistent with secondary pyridoxine-deficient encephalopathy. These patients
 highlight the importance of tissue non-specific alkaline phosphatase in the neuronal PLP-dependent metabolism of neurotransmitters.
 In addition, the disturbance of PLP metabolism appears to underlie the predominant neurological presentation in our patients.
 We recommend the measurement of serum alk...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155438</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:40 +0100</pubDate>
            <guid isPermaLink="false">3155438</guid>        </item>
        <item>
            <title>Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries</title>
            <link>http://www.medworm.com/index.php?rid=3155439&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw01834p3u5575913%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ultrastructural study of skin biopsies in two cases of Gaucher disease (GD) patients (types II and III) revealed hitherto
 unknown alteration of the blood capillary endothelial cells (ECs) featured by hypertrophy and numerous subplasmalemmal microvesicles
 underneath both the apical and basal membranes. There was also prominent apical membrane folding with formation of filiform
 and large cytoplasmic projections, with occasional transcapillary cytoplasmic bridges. Similar, though less frequently expressed,
 changes were manifested at the basal membrane by numerous cytoplasmic projections into the subendothelial space. Regressive
 changes with EC breakdown were rare. Lysosomal storage was always absent. Besides EC hypertrophy, there was also increased
 EC density in the ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155439</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:39 +0100</pubDate>
            <guid isPermaLink="false">3155439</guid>        </item>
        <item>
            <title>Fatty acid oxidation disorders: outcome and long-term prognosis</title>
            <link>http://www.medworm.com/index.php?rid=3155441&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5243p747k9466u46%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Assessing the outcome of fatty acid oxidation disorders is difficult, as most are rare. For diagnosis by newborn screening,
 the situation is compounded: far more cases are diagnosed by screening than by clinical presentation, representing a somewhat
 different cohort. The literature on outcome was reviewed. For disorders other than medium-chain acyl-coenzyme&amp;nbsp;A (CoA) dehydrogenase
 (MCAD) deficiency there was insufficient evidence to make many firm statements. In MCAD deficiency, risk of death in the first
 72&amp;nbsp;h is around 4%, with a further approximately 5–7% fatality rate in the first 6&amp;nbsp;years but very low subsequent risk in previously
 undiagnosed patients. The risk of death after diagnosis is very low at any age, with good management. The long-term ou...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155441</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:37 +0100</pubDate>
            <guid isPermaLink="false">3155441</guid>        </item>
        <item>
            <title>Tumoral calcinosis</title>
            <link>http://www.medworm.com/index.php?rid=3155440&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv13qnpj760653181%2F</link>
            <description>Content Type Journal ArticleCategory Images in Metabolic MedicineDOI 10.1007/s10545-009-9019-4Authors
		Mirian C. H. Janssen, Radboud University Medical Centre Department of General Internal Medicine PO Box 9101 6500 HB Nijmegen The NetherlandsRuud G. L. de Sévaux, Radboud University Medical Centre Department of Nephrology Nijmegen The Netherlands
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155440</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:37 +0100</pubDate>
            <guid isPermaLink="false">3155440</guid>        </item>
        <item>
            <title>Study of inborn errors of metabolism in urine from patients with unexplained mental retardation</title>
            <link>http://www.medworm.com/index.php?rid=3155442&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7827121727150h7%2F</link>
            <description>In conclusion, in patients with MR, it is essential to perform a thorough appraisal
 of the associated signs and symptoms, and in most disorders, it is necessary to apply specific analyses. In some cases, it
 is important to achieve an early diagnosis and therapy, which may reduce the morbimortality, and to offer genetic counselling.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-9004-yAuthors
		Angela Sempere, Pediatric Neurology, Hospital Sant Joan de Déu, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII Esplugues SpainAngela Arias, Hospital Clínic and CIBERER, ISCIII Division of Inborn Errors of Metabolism (IBC), Department of Biochemistry and Molecular Genetics Barcelona SpainGuillermo Farré, Hospital Clínic and CIBE...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155442</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:35 +0100</pubDate>
            <guid isPermaLink="false">3155442</guid>        </item>
        <item>
            <title>Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?</title>
            <link>http://www.medworm.com/index.php?rid=3155444&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb376432388q64712%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A 5-year-old girl was referred to the Department of Pediatrics and Neonatology, Guglielmo da Saliceto Hospital, Italy, because
 of growth retardation. Clinical and laboratory investigations showed pallor, hepatosplenomegaly, anemia and low/normal platelet
 count. Further investigations led to the diagnosis of Gaucher disease (GD). We believe this is the first report of growth
 hormone deficiency in a growth-retarded child with GD. After 1&amp;nbsp;year of imiglucerase replacement enzyme therapy, her bone age
 had normalized, linear growth rate had accelerated, and insulin growth factor-1 (IGF-1) and, perhaps more interestingly, growth
 hormone deficiency, had normalized. While the pathophysiological mechanisms underlying compromised growth in GD are poorly
 understood, the ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155444</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:33 +0100</pubDate>
            <guid isPermaLink="false">3155444</guid>        </item>
        <item>
            <title>Disease severity in sibling pairs with type 1 Gaucher disease</title>
            <link>http://www.medworm.com/index.php?rid=3155443&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb0482x1593j625v2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The only prognostic markers in Gaucher disease, the most common lysosomal storage disorder, are young age at first symptom/sign
 and the presence of null/severe mutations, both being predictive of more severe phenotypes. Therefore, it would be helpful
 to know whether siblings with the same genotype can be expected to experience comparable phenotypic expression. All non-neuronopathic
 sibling pairs in our referral clinic (1993–2008) with the same genotype were included. For each pair, gender, date of birth,
 severity score index at presentation, age at diagnosis and first symptom/sign, presence of bone involvement, spleen status,
 and use of enzyme replacement therapy were tabulated. There were 90 pairs of siblings: two sets of identical twins; 24 pairs
 of brothers, ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155443</comments>
            <pubDate>Mon, 04 Jan 2010 17:59:33 +0100</pubDate>
            <guid isPermaLink="false">3155443</guid>        </item>
        <item>
            <title>Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes—possibility for newborn screening</title>
            <link>http://www.medworm.com/index.php?rid=3121844&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx35622099022l137%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;The fluorometric technique for the assessment of GAA activity in DBS provides a reliable diagnosis for all variants of Pompe
 disease. The assay protocol could be simplified for neonatal screening, without increasing the false positive rate significantly
 or burdening the laboratory with time-consuming procedures.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-9003-zAuthors
		Zoltan Lukacs, University Medical Center of Hamburg-Eppendorf Institute of Clinical Chemistry Hamburg GermanyPaulina Nieves Cobos, University Medical Center of Hamburg-Eppendorf Institute of Clinical Chemistry Hamburg GermanyEugen Mengel, University of Mainz Department of Pediatrics Mainz GermanyRalf Hartung, University of Mainz Department of Pediatrics Mainz G...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3121844</comments>
            <pubDate>Wed, 23 Dec 2009 22:57:21 +0100</pubDate>
            <guid isPermaLink="false">3121844</guid>        </item>
        <item>
            <title>Zellweger syndrome with unusual findings: non-immune hydrops fetalis, dermal erythropoiesis and hypoplastic toe nails</title>
            <link>http://www.medworm.com/index.php?rid=3121846&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnl6rlv41633v873u%2F</link>
            <description>We report here on a
 Turkish patient who presented with unusual clinical findings, that included non-immune hydrops, dermal erythropoiesis and
 hypoplastic toenails, as well as common dysmorphic features of Zellweger syndrome. The patient has also pulmonary hypoplasia,
 which has been reported in only a few patients with Zellweger syndrome. A peroxisomal biogenesis disorder was confirmed by
 enzyme analysis and abnormal very long-chain fatty acid (VLCFA) profiles in plasma and fibroblast and immunofluorescence microscopy
 studies. Subsequent molecular genetic analysis revealed a homozygous c.856C&amp;gt;T mutation (R268X) in the PEX3 gene, which made this patient the third to have a defect in this gene. In contrast to those of the two previously reported
 patients, the cells of this patient st...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3121846</comments>
            <pubDate>Wed, 23 Dec 2009 22:57:20 +0100</pubDate>
            <guid isPermaLink="false">3121846</guid>        </item>
        <item>
            <title>Tyrosinemia type 1 and Angelman syndrome due to paternal uniparental isodisomy 15</title>
            <link>http://www.medworm.com/index.php?rid=3121845&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw1x85465w7822w2n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Uniparental isodisomy arises when an individual inherits two copies of a specific chromosome from a single parent, which can
 unmask a recessive mutation or cause a problem of genetic imprinting. Here we describe an exceptional case in which the patient
 simultaneously presents tyrosinemia type 1 and Angelman syndrome. The genetic studies showed that the patient presents paternal
 uniparental isodisomy of chromosome 15, with absence of the maternal homolog. As a consequence of this isodisomy, the patient
 is homozygous for the mutation IVS12+5G&amp;gt;A in the FAH gene, located in the chromosomal region 15q23-25, causing tyrosinemia type 1. The mutation was inherited from his father
 in double dosage, whereas the mother is not a carrier, which implies that the recurrence ri...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3121845</comments>
            <pubDate>Wed, 23 Dec 2009 22:57:20 +0100</pubDate>
            <guid isPermaLink="false">3121845</guid>        </item>
        <item>
            <title>False-positive newborn screening mimicking glutaric aciduria type I in infants with renal insufficiency</title>
            <link>http://www.medworm.com/index.php?rid=3121847&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw647u88777711300%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Glutaric aciduria type I (GA I), an autosomal-recessive deficiency of glutaryl-CoA-dehydrogenase, leads to encephalopathic
 crises resulting in irreversible neurological damage. As early diagnosis and implementation of appropriate treatment has significant
 benefit for these patients, GA I has been implemented in the extended newborn screening program in several countries. Screening
 parameter is glutarylcarnitine (C5DC) with its ratios. From 1 January 2005 until 31 December 2008, 173,846 newborns were examined
 by neonatal screening in our screening center. C5DC and/or at least three C5DC/acylcarnitine ratios were increased in 53 newborns
 (0.03%) and persisted in 11 infants after recall. GA I was not confirmed in any of these infants, but all 11 infants were
 sufferin...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3121847</comments>
            <pubDate>Wed, 23 Dec 2009 22:57:19 +0100</pubDate>
            <guid isPermaLink="false">3121847</guid>        </item>
        <item>
            <title>Increased prevalence of mutant null alleles that cause hereditary fructose intolerance in the American population</title>
            <link>http://www.medworm.com/index.php?rid=3121848&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F58873tl47k563863%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mutations in the aldolase B gene (ALDOB) impairing enzyme activity toward fructose-1-phosphate cleavage cause hereditary fructose intolerance (HFI). Diagnosis of
 the disease is possible by identifying known mutant ALDOB alleles in suspected patients; however, the frequencies of mutant alleles can differ by population. Here, 153 American HFI
 patients with 268 independent alleles were analyzed to identify the prevalence of seven known HFI-causing alleles (A149P,
 A174D, N334K, Δ4E4, R59Op, A337V, and L256P) in this population. Allele-specific oligonucleotide hybridization analysis was
 performed on polymerase chain reaction (PCR)-amplified genomic DNA from these patients. In the American population, the missense
 mutations A149P and A174D are the two most common allele...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3121848</comments>
            <pubDate>Wed, 23 Dec 2009 22:57:18 +0100</pubDate>
            <guid isPermaLink="false">3121848</guid>        </item>
        <item>
            <title>Erratum to: Prediction of outcome in isolated methylmalonic acidurias: combined use of clinical and biochemical parameters</title>
            <link>http://www.medworm.com/index.php?rid=3016821&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj2p8g722560l1585%2F</link>
            <description>Content Type Journal ArticleCategory ErratumDOI 10.1007/s10545-009-9957-xAuthors
		F. Hörster, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 430 69120 Heidelberg GermanyS. F. Garbade, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 430 69120 Heidelberg GermanyT. Zwickler, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 430 69120 Heidelberg GermanyH. I. Aydin, Hacettepe University Ankara Department of Metabolism, Children’s Hospital Ankara TurkeyO. A. Bodamer, Allgemeines Krankenhaus Department of Paediatrics Vienna AustriaA...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016821</comments>
            <pubDate>Thu, 19 Nov 2009 07:32:48 +0100</pubDate>
            <guid isPermaLink="false">3016821</guid>        </item>
        <item>
            <title>Psychological aspects of patients with Fabry disease</title>
            <link>http://www.medworm.com/index.php?rid=3016823&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh214712178471314%2F</link>
            <description>In this study, 28 patients with Fabry disease completed the MMPI-2 and a background questionnaire. Fabry disease patients
 scored significantly higher than the MMPI-2 normative sample on seven clinical scales (Hs, D, Hy, Pd, Pa, Pt, Sc) and two validity scales (L, F). Individuals with elevated scores on the Hs, D, and Hy scales tend to have somatic complaints, sadness, and emotional distress. Under stress, they may experience an increase in
 physical symptoms. Elevated Pd, Pa, Pt, and Sc scales suggest social maladjustment, suspiciousness, and feelings of isolation. An elevated L scale suggests defensiveness; a high score on F suggests emotional turmoil. When compared with cohorts of patients with Gaucher disease (GD), chronic heart disease (CRHD),
 and chronic pain, the Fabry disease pati...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016823</comments>
            <pubDate>Thu, 19 Nov 2009 07:32:36 +0100</pubDate>
            <guid isPermaLink="false">3016823</guid>        </item>
        <item>
            <title>PDH E1β deficiency with novel mutations in two patients with Leigh syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3016822&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh41435l8410h5t43%2F</link>
            <description>We report two patients with new mutations
 in PDHB and Leigh syndrome. Patient 1 was a boy with neonatal onset of hyperlactataemia, corpus callosum hypoplasia and a convulsive
 encephalopathy. After neurological deterioration, he died at age 5&amp;nbsp;months. Autopsy revealed the characteristic features of
 Leigh syndrome. Patient 2, also a boy, presented a milder clinical course. First symptoms were noticed at age 16&amp;nbsp;months with
 muscular hypotonia, lactic acidosis and recurrent episodes of somnolence and transient tetraparesis. MRI revealed bilateral
 signal hyperintensities in the globus pallidus, midbrain and crura cerebri. PDHc and E1 activities were deficient in fibroblasts in patient 1; in patient 2 PDHc deficiency was found in skeletal muscle. Mutations
 in PDHA1 were excluded. S...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016822</comments>
            <pubDate>Thu, 19 Nov 2009 07:32:36 +0100</pubDate>
            <guid isPermaLink="false">3016822</guid>        </item>
        <item>
            <title>Substrate deprivation therapy in juvenile Sandhoff disease</title>
            <link>http://www.medworm.com/index.php?rid=2971744&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7lv069654702r33%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Substrate deprivation therapy has been successfully applied in a number of lysosomal storage diseases, such as Gaucher disease.
 So far only limited experience is available in Sandhoff disease. We initiated substrate deprivation therapy in one male patient,
 who initially presented at the age of 3.5 years with epilepsy and regression in motor skills and speech development. Juvenile
 Sandhoff disease was diagnosed on the basis of a decreased hexosaminidase activity in leukocytes and a homozygous HEXB gene mutation. After the epilepsy was controlled, the clinical course remained stable for years, defined by a mild proximal
 myopathy and stable mental retardation. At 14 years of age the patient experienced a second episode with progressively worsening
 general condition wit...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971744</comments>
            <pubDate>Fri, 06 Nov 2009 19:34:22 +0100</pubDate>
            <guid isPermaLink="false">2971744</guid>        </item>
        <item>
            <title>Miglustat therapy in juvenile Sandhoff disease</title>
            <link>http://www.medworm.com/index.php?rid=2971745&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu2u8852j3g068556%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;GM2-gangliosidosis is a rare and heterogeneous inherited metabolic disorder caused by autosomal recessive mutations in genes
 encoding the lysosomal enzyme β-hexosaminidase, resulting in the accumulation of ganglioside GM2 in various tissues, particularly the central nervous system. It is characterized by progressive neurological deterioration
 that mainly affects motor and spinocerebellar function. Several forms of GM2-gangliosidosis exist, including the Sandhoff variant. Currently there is no treatment for these conditions, except for palliative
 care. Miglustat (Zavesca) is a reversible inhibitor of glucosylceramide synthase, which catalyses the first committed step
 in the synthesis of glucose-based glycolipids. Miglustat has pharmacokinetic properties that allow it...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971745</comments>
            <pubDate>Fri, 06 Nov 2009 19:34:21 +0100</pubDate>
            <guid isPermaLink="false">2971745</guid>        </item>
        <item>
            <title>Heterozygous familial hypercholesterolaemia in childhood: Cardiovascular risk prevention</title>
            <link>http://www.medworm.com/index.php?rid=2971746&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu777j213665135l5%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Children with familial hypercholesterolaemia (FH) have severely increased low-density lipoprotein cholesterol (LDL-C) levels
 that strongly predispose to premature cardiovascular disease (CVD) later in life. Early identification makes it possible to
 start lipid-lowering therapy at young age to prevent CVD. The atherosclerotic process can be inhibited by potent lipid-lowering
 therapy. The cornerstone of lipid-lowering therapy is a healthy lifestyle, but most of the time this is insufficient to reach
 adequate LDL-C goals. Subsequently, pharmacological therapy is initiated with increasing frequency. In the past decade numerous
 studies have assessed the efficacy and safety of statins in children with FH. Those studies demonstrate that statins are well
 tolerated, safe an...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971746</comments>
            <pubDate>Fri, 06 Nov 2009 19:34:19 +0100</pubDate>
            <guid isPermaLink="false">2971746</guid>        </item>
        <item>
            <title>Scheie syndrome: Enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression</title>
            <link>http://www.medworm.com/index.php?rid=2971747&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu74x2630m1715826%2F</link>
            <description>We report a 38-year-old female Scheie patient who has been on ERT for 8&amp;nbsp;years. While non-neurological symptoms improved, she
 developed paresthesias in her hands and feet and progressive pain in her legs. Somatosensory evoked potentials were abnormal,
 suggesting dysfunction of the dorsal funiculus and lemniscus medialis. After 6&amp;nbsp;years of ERT, a spinal MRI showed dural thickening
 at the upper cervical spine. These soft-tissue deposits are presumably due to the accumulation of mucopolysaccharides. Intramedullary
 hyperintensities at the level of C1/2 revealed cervical myelopathy. An MRI before the start of ERT had shown milder spinal
 lesions. Cystic lesions in the white matter of the centrum semiovale due to dilated Virchow–Robin spaces were essentially
 unchanged compared wit...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971747</comments>
            <pubDate>Thu, 05 Nov 2009 18:42:04 +0100</pubDate>
            <guid isPermaLink="false">2971747</guid>        </item>
        <item>
            <title>Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey</title>
            <link>http://www.medworm.com/index.php?rid=2948156&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc4h8g50778356331%2F</link>
            <description>Conclusions: Hearing loss is a well-known clinical manifestation in patients with Fabry disease. It was reported in significant numbers
 of children in the FOS signs and symptoms questionnaire, but confirmed in only 19% by formal audiometry. The subjective hearing
 impairment may have been due to middle-ear effusions in many cases. Tinnitus is a well-recognized symptom in Fabry disease
 and can present in childhood. The presence of tinnitus correlated with overall disease severity.
 
	Content Type Journal ArticleCategory ORIGINAL ARTICLEDOI 10.1007/s10545-009-1290-xAuthors
		A. Keilmann, University Hospital Department for ENT and Communication Disorders Langenbeckstr. 1 55101 Mainz GermanyD. Hajioff, Southmead Hospital Department of Otolaryngology Bristol UKU. Ramaswami, Addenbrooke’s Un...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2948156</comments>
            <pubDate>Fri, 30 Oct 2009 07:37:28 +0100</pubDate>
            <guid isPermaLink="false">2948156</guid>        </item>
        <item>
            <title>RFT1-CDG: Deafness as a novel feature of congenital disorders of glycosylation</title>
            <link>http://www.medworm.com/index.php?rid=2930067&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F12465889652u3844%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Congenital disorders of glycosylation (CDG) are genetic diseases due to defects in the synthesis of glycans and in the attachment
 of glycans to lipids and proteins. Actually, some 42 CDG are known including defects in protein N-glycosylation, in protein
 O-glycosylation, in lipid glycosylation, and in multiple and other glycosylation pathways. Most CDG are multisystem diseases
 and a large number of signs and symptoms have already been reported in CDG. An exception to this is deafness. This symptom
 has not been observed as a consistent feature in CDG. In 2008, a novel defect was identified in protein N-glycosylation, namely
 in RFT1. This is a defect in the assembly of N-glycans. RFT1 is involved in the transfer of Man5GlcNAc2-PP-Dol from the cytoplasmic to the luminal...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2930067</comments>
            <pubDate>Sat, 24 Oct 2009 07:55:20 +0100</pubDate>
            <guid isPermaLink="false">2930067</guid>        </item>
        <item>
            <title>Cognitive and social profiles in two patients with cobalamin C disease</title>
            <link>http://www.medworm.com/index.php?rid=2897685&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1g30776l86168170%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Cobalamin C (cblC) disease, an inborn error of vitamin B12 metabolism, results in neurometabolic, neurochemical and neuroanatomical changes. Little is known of the long-term effects
 of the disorder on cognition and behaviour in children. Here, the complete neuropsychological profiles of two 12-year-old
 girls with cblC disease are presented. The two girls were tested longitudinally with standardized neuropsychological tests
 including intellectual ability, attention and memory, as well as executive, adaptive and behavioural function. The results
 indicate the presence of intellectual dysfunction, attention problems, and concerns with behavioural aspects of executive
 function. Both patients demonstrated a pattern of decreasing intellectual function over time, which may ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2897685</comments>
            <pubDate>Wed, 14 Oct 2009 17:17:42 +0100</pubDate>
            <guid isPermaLink="false">2897685</guid>        </item>
        <item>
            <title>Novel mutation affecting the pterin-binding site of PTS gene and review of PTS mutations in Thai patients with 6-pyruvoyltetrahydropterin synthase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2897686&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0227503441l86032%2F</link>
            <description>In conclusion, severe neurological impairment from BH4 deficiency could be prevented by newborn screening for HPA and proper metabolic management. However, pterin analysis for
 early diagnosis of BH4 deficiency is still not available in most developing countries.
 
	Content Type Journal ArticleCategory CASE REPORTDOI 10.1007/s10545-009-1221-xAuthors
		N. Vatanavicharn, Faculty of Medicine Siriraj Hospital Division of Medical Genetics, Department of Pediatrics 2 Prannok Road, Bangkoknoi Bangkok Thailand 10700C. Kuptanon, Faculty of Medicine Siriraj Hospital Division of Medical Genetics, Department of Pediatrics 2 Prannok Road, Bangkoknoi Bangkok Thailand 10700S. Liammongkolkul, Faculty of Medicine Siriraj Hospital Division of Medical Genetics, Department of Pediatrics 2 Prannok Road, Bangko...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2897686</comments>
            <pubDate>Wed, 14 Oct 2009 17:17:40 +0100</pubDate>
            <guid isPermaLink="false">2897686</guid>        </item>
        <item>
            <title>Development and implementation of a novel assay for l-2-hydroxyglutarate dehydrogenase (l-2-HGDH) in cell lysates: l-2-HGDH deficiency in 15 patients with l-2-hydroxyglutaric aciduria</title>
            <link>http://www.medworm.com/index.php?rid=2889435&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq57348h146555113%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;
 l-2-hydroxyglutaric aciduria (l-2-HGA) is a rare inherited autosomal recessive neurometabolic disorder caused by mutations in the gene encoding l-2-hydroxyglutarate dehydrogenase. An assay to evaluate l-2-hydroxyglutarate dehydrogenase (l-2-HGDH) activity in fibroblast, lymphoblast and/or lymphocyte lysates has hitherto been unavailable. We developed an l-2-HGDH enzyme assay in cell lysates based on the conversion of stable-isotope-labelled l-2-hydroxyglutarate to 2-ketoglutarate, which is converted into l-glutamate in situ. The formation of stable isotope labelled l-glutamate is therefore a direct measure of l-2-HGDH activity, and this product is detected by liquid chromatography-tandem mass spectrometry. A deficiency of l-2-HGDH activity was detected in cell lysates ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889435</comments>
            <pubDate>Sun, 11 Oct 2009 05:59:05 +0100</pubDate>
            <guid isPermaLink="false">2889435</guid>        </item>
        <item>
            <title>Clinical and biochemical studies in mucopolysaccharidosis type II carriers</title>
            <link>http://www.medworm.com/index.php?rid=2889437&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy2r4366636551u54%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;The aim of the study was to characterize clinically and biochemically mucopolysaccharidosis type II (MPS II) heterozygotes.
 Fifty-two women at risk to be a carrier, with a mean age of 34.1&amp;nbsp;years (range 16–57&amp;nbsp;years), were evaluated through pedigree
 analysis, medical history, physical examination, measurement of iduronate sulfatase (IDS) activities in plasma and in leukocytes,
 quantification of glycosaminoglycans (GAGs) in urine, and analysis of the IDS gene. Eligibility criteria for the study also included being 16&amp;nbsp;years of age or older and being enrolled in a genetic counselling
 programme. The pedigree and DNA analyses allowed the identification of 40/52 carriers and 12/52 non-carriers. All women evaluated
 were clinically healthy, and their levels o...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889437</comments>
            <pubDate>Sun, 11 Oct 2009 05:59:03 +0100</pubDate>
            <guid isPermaLink="false">2889437</guid>        </item>
        <item>
            <title>Hydroxocobalamin dose escalation improves metabolic control in cblC</title>
            <link>http://www.medworm.com/index.php?rid=2889436&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0p1605802xg70458%2F</link>
            <description>We describe the biochemical response of a 13-year-old boy with worsening
 metabolic parameters despite strict adherence to a conventional treatment regimen. We progressively increased the OHCbl dose
 from 1 to 20&amp;nbsp;mg IM per day and observed a dose-dependent response with an 80% reduction of plasma MMA (25 to 5.14&amp;nbsp;μmol/L;
 normal range &amp;lt;0.27&amp;nbsp;μmol/L), a 55% reduction of tHcy (112 to 50&amp;nbsp;μmol/L; normal range: 0–13&amp;nbsp;μmol/L) and a greater than twofold
 increase in methionine (17 to 36&amp;nbsp;μmol/L; normal range: 7–47&amp;nbsp;μmol/L). This suggests that higher OHCbl doses might be required
 to achieve an optimal biochemical response in cblC patients, but it is unknown whether it may slow or eliminate other complications.
 Future clinical trials to determine the ben...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889436</comments>
            <pubDate>Sun, 11 Oct 2009 05:59:03 +0100</pubDate>
            <guid isPermaLink="false">2889436</guid>        </item>
        <item>
            <title>Mitochondria and diabetes mellitus: untangling a conflictive relationship?</title>
            <link>http://www.medworm.com/index.php?rid=2889440&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn8528t4275908715%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Diabetes mellitus is occasionally observed in patients with skeletal muscle respiratory chain deficiency, suggesting that
 skeletal muscle mitochondrial dysfunction might play a pathogenic role in type 2 diabetes (T2D). In support of this hypothesis,
 decreased muscle mitochondrial activity has been reported in T2D patients and in mouse models of diabetes. However, recent
 work by several groups suggests that decreased muscle mitochondrial function may be a consequence rather than a cause of diabetes,
 since decreased mitochondrial function in mice affords protection from diabetes and obesity. We review the data on this controversial
 but important issue of potential links between mitochondrial dysfunction and diabetes.
 
	Content Type Journal ArticleCategory REVIEWDOI 1...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889440</comments>
            <pubDate>Sun, 11 Oct 2009 05:59:02 +0100</pubDate>
            <guid isPermaLink="false">2889440</guid>        </item>
        <item>
            <title>Effort bruising disclosing Gaucher disease in a 55-year-old non-Jewish woman</title>
            <link>http://www.medworm.com/index.php?rid=2889439&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx0j01270x11r22q8%2F</link>
            <description>Content Type Journal ArticleCategory IMAGES IN METABOLIC MEDICINEDOI 10.1007/s10545-009-1217-6Authors
		M. Machaczka, Karolinska University Hospital Huddinge Hematology Center Karolinska M54, SE-141 86 Stockholm SwedenM. Klimkowska, Karolinska University Hospital Huddinge Department of Pathology Stockholm SwedenH. Hägglund, Karolinska University Hospital Huddinge Hematology Center Karolinska M54, SE-141 86 Stockholm Sweden
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889439</comments>
            <pubDate>Sun, 11 Oct 2009 05:59:02 +0100</pubDate>
            <guid isPermaLink="false">2889439</guid>        </item>
        <item>
            <title>Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD)</title>
            <link>http://www.medworm.com/index.php?rid=2889438&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F73509022t7102h65%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive disorder of mitochondrial fatty acid oxidation
 which is usually diagnosed in infancy or through neonatal screening. In the absence of population screening, adults with undiagnosed
 MCADD can be expected. This review discusses 14 cases that were identified during adulthood. The mortality of infantile patients
 is approximately 25% whereas in this adult case series it was shown it to be 50% in acutely presenting patients and 29% in
 total. Therefore, undiagnosed individuals are at risk of sudden fatal metabolic decompensation with high mortality. This review
 illustrates the need to consider the possibility of a fatty acid oxidation defect in an adult who presents with unexplained
 sudden cli...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889438</comments>
            <pubDate>Sun, 11 Oct 2009 05:59:02 +0100</pubDate>
            <guid isPermaLink="false">2889438</guid>        </item>
        <item>
            <title>Long-term exposure of human proximal tubule cells to hydroxycobalamin[c-lactam] as a possible model to study renal disease in methylmalonic acidurias</title>
            <link>http://www.medworm.com/index.php?rid=2881034&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw2q71520373447t5%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Dysfunction of proximal tubules resulting in tubulointerstitial nephritis and chronic renal failure is a frequent long-term
 complication of methylmalonic acidurias. However, the underlying pathomechanisms have not yet been extensively studied owing
 to the lack of suitable in vitro and in vivo models. Application of hydroxycobalamin[c-lactam] has been shown to inhibit the
 metabolism of hydroxycobalamin and, thereby, to induce methylmalonic aciduria in rats, oligodendrocytes, and rat hepatocytes.
 Our study characterizes the biochemical and bioenergetic effects of long-term exposure of human proximal tubule cells to hydroxycobalamin[c-lactam],
 aiming to establish a novel in vitro model for the renal pathogenesis of methylmalonic acidurias. Incubation of human proximal
...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2881034</comments>
            <pubDate>Fri, 09 Oct 2009 06:24:36 +0100</pubDate>
            <guid isPermaLink="false">2881034</guid>        </item>
        <item>
            <title>Pathophysiology of fatty acid oxidation disorders</title>
            <link>http://www.medworm.com/index.php?rid=2881036&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv2718x571843u821%2F</link>
            <description>This article provides an overview of the pathogenesis of fatty acid oxidation disorders. It describes the different
 tissue involvement with the disease processes and correlates disease phenotype with the nature of the genetic defect for the
 known disorders of the pathway.
 
	Content Type Journal ArticleCategory Fatty Acid OxidationDOI 10.1007/s10545-009-1294-6Authors
		M. J. Bennett, University of Pennsylvania and Children’s Hospital of Philadelphia Department of Pathology &amp; Laboratory Medicine 34th Street &amp; Civic Center Blvd, 5NW58 Philadelphia PA 19104 USA
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2881036</comments>
            <pubDate>Fri, 09 Oct 2009 06:24:34 +0100</pubDate>
            <guid isPermaLink="false">2881036</guid>        </item>
        <item>
            <title>Remarkable differences: the course of life of young adults with galactosaemia and PKU</title>
            <link>http://www.medworm.com/index.php?rid=2881035&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5244g8381tm85155%2F</link>
            <description>This study investigated the CoL and the social demographical outcomes in these young adults with galactosaemia,
 and compared them with the general population and with PKU patients. A total of 15 (88%) adult patients with classical galactosaemia
 participated in this study. Classical galactosaemia patients had a delayed social and psychosexual development compared to
 their peers from the general population and to PKU patients. Also, they were significantly less frequently married or living
 together and significantly less frequently employed than the general population. Our study shows a stark contrast between
 patients with galactosaemia and patients with PKU, although both are diagnosed in the neonatal period and need life-long dietary
 restrictions. The observed difference is likely du...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2881035</comments>
            <pubDate>Fri, 09 Oct 2009 06:24:34 +0100</pubDate>
            <guid isPermaLink="false">2881035</guid>        </item>
        <item>
            <title>Secondary disorders of glycosylation in inborn errors of fructose metabolism</title>
            <link>http://www.medworm.com/index.php?rid=2818203&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr676340002661121%2F</link>
            <description>We describe a girl with neonatal hypertonia, facial trismus, absent swallowing and coughing reflexes,
 gastro-oesophageal reflux and sporadically elevated Krebs cycle metabolites and lactate. At 14&amp;nbsp;months microcephaly and hepatomegaly
 were noted, with hypertransaminasaemia but normal blood coagulation, glucose, phosphate, and absent urinary reducing substances.
 Neurological impairment persisted. Because of hepatic and neurological abnormalities with developmental delay, Tf IEF was
 performed and showed a severe type 1 pattern, resulting in a wrong diagnosis of CDG. Subsequently, an aversion to fruits suggested
 HFI, confirmed by the finding of ALDOB mutations (p.A150P/p.N335K). The girl improved with fructose-free diet, but liver cirrhosis led to hepatic transplantation.
 She is now...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2818203</comments>
            <pubDate>Sun, 20 Sep 2009 05:36:19 +0100</pubDate>
            <guid isPermaLink="false">2818203</guid>        </item>
        <item>
            <title>Prevalence of classical phenylketonuria in mentally retarded individuals in Iran</title>
            <link>http://www.medworm.com/index.php?rid=2811984&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F041083011011pr85%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Using Guthrie Biological Inhibition Assay, 4963 mentally retarded individuals housed in 31 cities and towns across the country
 were screened for PKU. The average prevalence of classical PKU in the study population was 2.1%, which is higher than that
 reported for most mentally retarded populations in other countries prior to the implementation of a nationwide newborn screening
 programme for PKU. The prevalence of PKU in 1814 mentally retarded inmates housed in shelters in Tehran was 2.81%, and the
 prevalence of the disease in 3149 inmates sheltered in other cities and towns was 1.68%. It appears that most of the difference
 between the prevalence of PKU in these two populations is due to a unique PKU referral pattern in Iran. The high prevalence
 of PKU in the mentall...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811984</comments>
            <pubDate>Fri, 18 Sep 2009 16:27:21 +0100</pubDate>
            <guid isPermaLink="false">2811984</guid>        </item>
        <item>
            <title>Neurometabolic disorders</title>
            <link>http://www.medworm.com/index.php?rid=2811985&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ftk06337834754672%2F</link>
            <description>Content Type Journal ArticleCategory EDITORIALDOI 10.1007/s10545-009-9958-9Authors
		Jean-Marie Saudubray, Assistance Publique Hôpitaux de Paris et Université Pierre et Marie Curie (Paris VI) Departement des maladies métaboliques, Federation des maladies du système nerveux Hôpital Pitié-Salpêtrière Paris France
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811985</comments>
            <pubDate>Wed, 16 Sep 2009 13:15:01 +0100</pubDate>
            <guid isPermaLink="false">2811985</guid>        </item>
        <item>
            <title>High incidence of profound biotinidase deficiency detected in newborn screening blood spots in the Somalian population in Minnesota</title>
            <link>http://www.medworm.com/index.php?rid=2811987&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr7815549w7728174%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Newborns identified with profound biotinidase deficiency (BTD) by the Minnesota Newborn Screening Program (MN NBS) between
 1 October 2004 and 30 May 2008 were all from new immigrant groups. Thirty-three positive cases of BTD were identified out
 of 264 727 infants screened by the Wolf colorimetric system during the period of this study by MN NBS. Five cases of profound
 BTD (0.1 to &amp;lt;0.6&amp;nbsp;nmol/min per ml) and 26 cases of partial BTD (0.9 to 2.3&amp;nbsp;nmol/min per ml) were later confirmed through measurement
 of serum biotinidase activity. The incidence of combined partial and profound BTD of 1/8540 and that of profound BTD of 1/52
 945 in Minnesota are unusually high in comparison with the reported worldwide numbers of 1/61 067 for combined BTD and 1/137
 401 for p...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811987</comments>
            <pubDate>Wed, 16 Sep 2009 13:15:00 +0100</pubDate>
            <guid isPermaLink="false">2811987</guid>        </item>
        <item>
            <title>Retinal detachment causing unilateral blindness in a 12-year-old girl with gyrate atrophy</title>
            <link>http://www.medworm.com/index.php?rid=2811986&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F26xgmn06871q56t4%2F</link>
            <description>Content Type Journal ArticleCategory IMAGES IN METABOLIC MEDICINEDOI 10.1007/s10545-009-1220-yAuthors
		C. P. Barnett, Division of Ophthalmology, The Hospital for Sick Children Division of Clinical and Metabolic Genetics 555 University Ave Toronto Ontario Canada M5G 1X8W.-C. Lam, Division of Ophthalmology, The Hospital for Sick Children Division of Clinical and Metabolic Genetics 555 University Ave Toronto Ontario Canada M5G 1X8A. Schulze, Division of Ophthalmology, The Hospital for Sick Children Division of Clinical and Metabolic Genetics 555 University Ave Toronto Ontario Canada M5G 1X8
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811986</comments>
            <pubDate>Wed, 16 Sep 2009 13:15:00 +0100</pubDate>
            <guid isPermaLink="false">2811986</guid>        </item>
        <item>
            <title>Inborn errors of metabolism and motor disturbances in children</title>
            <link>http://www.medworm.com/index.php?rid=2811988&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F91027j732hq17641%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Motor disturbances are very common in paediatric neurology. Often families can be reassured that these are just variants of
 normal development. However, abnormal movements can also be the hallmark of severe brain dysfunction of different and complex
 origins. This review concentrates on motor disturbances as frequent and important symptoms of inborn errors of metabolism.
 A structured diagnostic approach is developed taking into account age-dependent physiological developments and pathophysiological
 responses of gross and fine motor functions. A series of investigations are presented with the primary aim of early diagnosis
 of treatable conditions. The correct recognition and differentiation of movement disorders (ataxia, rigid akinetic syndrome
 (‘parkinsonism’), ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811988</comments>
            <pubDate>Wed, 16 Sep 2009 13:14:58 +0100</pubDate>
            <guid isPermaLink="false">2811988</guid>        </item>
        <item>
            <title>Cardiomyopathy in the congenital disorders of glycosylation (CDG): a case of late presentation and literature review</title>
            <link>http://www.medworm.com/index.php?rid=2811989&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq2h1101233t20770%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;The congenital disorders of glycosylation (CDG) are a recently described group of inherited multisystem disorders characterized
 by defects predominantly of N- and O-glycosylation of proteins. Cardiomyopathy in CDG has previously been described in several subtypes; it is usually associated
 with high morbidity and mortality and the majority of cases present in the first 2&amp;nbsp;years of life. This is the first case with
 presentation in late childhood and the article reviews current literature. An 11-year-old female with a background of learning
 difficulties presented in cardiac failure secondary to severe dilated cardiomyopathy. Prior to the diagnosis of CDG, her condition
 deteriorated; she required mechanical support (Excor Berlin Heart) and was listed for cardiac tra...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811989</comments>
            <pubDate>Wed, 16 Sep 2009 13:14:56 +0100</pubDate>
            <guid isPermaLink="false">2811989</guid>        </item>
        <item>
            <title>Diagnosis, treatment, follow-up and gene mutation analysis in four Chinese children with biotinidase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2768088&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F644004t24118x637%2F</link>
            <description>Conclusions: Early recognition of biotinidase deficiency is crucial to avoid permanent damage. Determination of biotinidase activity
 should be included in neonatal screening in China. Exon 4 may be a hot-spot for biotinidase gene mutations in Chinese patients.
 Four novel gene variations may be disease-causing mutations and should be confirmed by expression studies.
 
	Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10545-009-1238-1Authors
		J. Ye, Shanghai Jiao Tong University School of Medicine, Shanghai Institute for Pediatric Research Department of Pediatric Endocrinology and Genetic Metabolism, Xin Hua Hospital 1665 Kong Jiang Road Shanghai 200092 ChinaT. Wang, Shanghai Jiao Tong University School of Medicine, Shanghai Institute for Pediatric Research Department of Pedi...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2768088</comments>
            <pubDate>Thu, 03 Sep 2009 06:41:28 +0100</pubDate>
            <guid isPermaLink="false">2768088</guid>        </item>
        <item>
            <title>Diagnosis of glutathione synthetase deficiency in newborn screening</title>
            <link>http://www.medworm.com/index.php?rid=2768087&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fep4p57h586u33754%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Glutathione synthetase (GSS) deficiency is a rare disorder of glutathione metabolism with varying clinical severity. Patients
 may present with haemolytic anaemia alone or together with acidosis and central nervous system impairment. Diagnosis is made
 by clinical presentation and detection of elevated concentrations of 5-oxoproline in urine and low GSS activity in erythrocytes
 or cultured skin fibroblasts. Diagnosis can be confirmed by mutational analysis. Treatment consists of the correction of acidosis,
 blood transfusion, and supplementation with antioxidants. The most important determinants for outcome and survival in patients
 with GSS deficiency are early diagnosis and early initiation of treatment. The case of a newborn with GSS deficiency diagnosed
 by tandem m...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2768087</comments>
            <pubDate>Thu, 03 Sep 2009 06:41:28 +0100</pubDate>
            <guid isPermaLink="false">2768087</guid>        </item>
        <item>
            <title>Total oxidant-scavenging capacities of plasma from glycogen storage disease type Ia patients as measured by cyclic voltammetry, FRAP and luminescence techniques</title>
            <link>http://www.medworm.com/index.php?rid=2768089&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw0v757l1w803j050%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;It has been suggested that the very low incidence of atherosclerosis in glycogen storage disease type Ia (GSD Ia) subjects
 might be attributed to elevated levels of uric acid, one of the potent low-molecular-weight antioxidants found in plasma.
 The present communication describes a use of two analytical methods—cyclic voltammetry and ferric reducing ability of plasma—and
 also two chemiluminescence methods to evaluate the total oxidant-scavenging capacities (TOSC) of plasma from GSD Ia patients.
 Our results verified the elevation of TOSC in GSD Ia patients and we propose the inclusion of luminescence and cyclic voltammetry
 assays as reliable methods for estimating TOSC in a variety of clinical disorders. Our findings with the cyclic voltammetry
 method add suppor...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2768089</comments>
            <pubDate>Thu, 03 Sep 2009 06:41:27 +0100</pubDate>
            <guid isPermaLink="false">2768089</guid>        </item>
        <item>
            <title>Insidious peripheral neuropathy occurring under treatment in infantile MTHFR deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2724084&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqr783079v0731516%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;5,10-Methylenetetrahydrofolate reductase (MTHFR) deficiency was diagnosed in a 1-month-old baby with signs of cerebral distress.
 Under a classic treatment using methionine supplementation, methyl donor (betaine) folinic acid, vitamin B6 and vitamin B12, the neuromotor development was satisfactory. At 15&amp;nbsp;years of age, however, despite no clear modification of the biochemical
 markers in body fluids, she developed a clinically overt peripheral axonal neuropathy. Only partial clinical improvement was
 obtained after reinforcement of betaine doses. Surveillance of the peripheral nerve is indicated in MTHFR deficiency, including
 in the infantile form with a good therapeutic compliance.
 
	Content Type Journal ArticleCategory Short ReportDOI 10.1007/s10545-009-1240-7Aut...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2724084</comments>
            <pubDate>Thu, 20 Aug 2009 19:58:03 +0100</pubDate>
            <guid isPermaLink="false">2724084</guid>        </item>
        <item>
            <title>A new case of ALG8 deficiency (CDG Ih)</title>
            <link>http://www.medworm.com/index.php?rid=2715015&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhv4333371176n6q4%2F</link>
            <description>Conclusion: The prognosis of patients with ALG8 deficiency is unfavourable. The majority of affected children have early onset of the
 disease with heterogeneous symptoms including multiple organ dysfunction, coagulopathy and protein-losing enteropathy. Neurological
 impairment is not a general clinical symptom, but it has to be taken into consideration when thinking about ALG8 deficiency.
 
	Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10545-009-1203-zAuthors
		K. Vesela, Charles University Department of Pediatrics, First Faculty of Medicine Ke Karlovu 2 128 08 Prague 2 Czech RepublicT. Honzik, Charles University Department of Pediatrics, First Faculty of Medicine Ke Karlovu 2 128 08 Prague 2 Czech RepublicH. Hansikova, Charles University Department of Pediatrics, First F...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2715015</comments>
            <pubDate>Tue, 18 Aug 2009 08:26:41 +0100</pubDate>
            <guid isPermaLink="false">2715015</guid>        </item>
        <item>
            <title>Glyceryl triacetate for Canavan disease: A low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model</title>
            <link>http://www.medworm.com/index.php?rid=2707948&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp22j531r85307636%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Canavan disease (CD) is a fatal dysmyelinating genetic disorder associated with aspartoacylase deficiency, resulting in decreased
 brain acetate levels and reduced myelin lipid synthesis in the developing brain. Here we tested tolerability of a potent acetate
 precursor, glyceryl triacetate (GTA), at low doses in two infants diagnosed with CD, aged 8 and 13&amp;nbsp;months. Much higher doses
 of GTA were evaluated for toxicity in the tremor rat model of CD. GTA was given orally to the infants for up to 4.5 and 6&amp;nbsp;months,
 starting at 25&amp;nbsp;mg/kg twice daily, doubling the dose weekly until a maximum of 250&amp;nbsp;mg/kg reached. Wild-type and tremor rat
 pups were given GTA orally twice daily, initially at a dose of 4.2&amp;nbsp;g/kg from postnatal days 7 through 14, and at 5....</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2707948</comments>
            <pubDate>Fri, 14 Aug 2009 16:54:47 +0100</pubDate>
            <guid isPermaLink="false">2707948</guid>        </item>
        <item>
            <title>Mental retardation and inborn errors of metabolism</title>
            <link>http://www.medworm.com/index.php?rid=2707947&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0r210504323628x2%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;In countries where clinical phenylketonuria is detected by newborn screening inborn errors of metabolism are rare causes of
 isolated mental retardation. There is no international agreement about what type of metabolic tests must be applied in patients
 with unspecific mental retardation. However, and although infrequent, there are a number of inborn errors of metabolism that
 can present in this way. Because of the high recurrence risk and the possibility of specific therapies, guidelines need to
 be developed and adapted to different populations. The application of a universal protocol may result in a low diagnostic
 performance in individual ethnic populations. Consideration of associated signs (extraneurological manifestations, psychiatric
 signs, autistic traits, ce...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2707947</comments>
            <pubDate>Fri, 14 Aug 2009 16:54:47 +0100</pubDate>
            <guid isPermaLink="false">2707947</guid>        </item>
        <item>
            <title>Management of neuronopathic Gaucher disease: Revised recommendations</title>
            <link>http://www.medworm.com/index.php?rid=2680948&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk0053551261l9n07%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;The original guidelines drawn up for the management of the neuronopathic forms of Gaucher disease were felt to be in need
 of revision; in particular, the role of high-dose enzyme replacement therapy (120&amp;nbsp;IU/kg of body weight every 2 weeks) in stabilizing
 neurological disease. The existing published evidence was analysed; it was concluded that it did not support the role of high-dose
 ERT, although this might be required to treat severe visceral disease.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-1164-2Authors
		A. Vellodi, Metabolic Unit, Great Ormond Street Hospital for Children NHS Trust Great Ormond Street WC1N 3JH London UKA. Tylki-Szymanska, The Children’s Memorial Health Institute Warsaw PolandE. H. Davies, Institute of ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2680948</comments>
            <pubDate>Tue, 04 Aug 2009 21:36:05 +0100</pubDate>
            <guid isPermaLink="false">2680948</guid>        </item>
        <item>
            <title>Epilepsy and inborn errors of metabolism in children</title>
            <link>http://www.medworm.com/index.php?rid=2662226&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F17401027x53117nt%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Epilepsy is a frequent symptom in inborn errors of metabolism, with virtually no specific seizure types or EEG signatures.
 It is most important to look quickly for those few inborn errors of metabolism in which specific therapies such as supplementation
 of cofactors or diets can make all the difference. If these investigations remain negative, epilepsy has to be treated with
 conventional antiepileptic drugs. Still, epilepsy is a potentially treatable symptom of many inborn errors of metabolism,
 and optimal treatment is of great importance for patients and their families.
 
	Content Type Journal ArticleCategory REVIEWDOI 10.1007/s10545-009-1171-3Authors
		N. I. Wolf, VU University Medical Center (VUMC) Department of Child Neurology Postbus 7057 1007 MB Amsterdam The N...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2662226</comments>
            <pubDate>Thu, 30 Jul 2009 07:49:46 +0100</pubDate>
            <guid isPermaLink="false">2662226</guid>        </item>
        <item>
            <title>Prediction of outcome in isolated methylmalonic acidurias: combined use of clinical and biochemical parameters</title>
            <link>http://www.medworm.com/index.php?rid=2662227&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg55r0888j4084103%2F</link>
            <description>Conclusion Outcome in MMAurias is best predicted by the enzymatic subgroup, cobalamin responsiveness, age at onset and birth decade.
 The prognosis is still unfavourable in patients with neonatal metabolic crises and non-responsiveness to cobalamin, in particular
 mut0 patients.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-1189-6Authors
		F. Hörster, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 430 D-69120 Heidelberg GermanyS. F. Garbade, University Children’s Hospital Heidelberg Department of General Pediatrics, Division of Inborn Metabolic Diseases Im Neuenheimer Feld 430 D-69120 Heidelberg GermanyT. Zwickler, University Children’s Hospital Heidelberg Departme...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2662227</comments>
            <pubDate>Thu, 30 Jul 2009 07:49:42 +0100</pubDate>
            <guid isPermaLink="false">2662227</guid>        </item>
        <item>
            <title>A cognitively normal PDH-deficient 18-year-old man carrying the R263G mutation in the PDHA1 gene</title>
            <link>http://www.medworm.com/index.php?rid=2662228&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fwh8164tp1n0g7r7n%2F</link>
            <description>We report a case with a previously known common mutation in PDHA1 (R263G) with an excellent outcome at 18&amp;nbsp;years of age. Previous
 patients with this mutation have presented with mental retardation and/or Leigh syndrome, while our patient’s clinical outcome
 is exceptional. He is cognitively normal and has normal brain MRI. His management includes a stringent carbohydrate-free diet,
 as well as supplementation with thiamine, carnitine and vitamin E. This case further broadens the clinical spectrum, including
 now an example of a cognitively normal adult with PDH deficiency.
 
	Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10545-009-1101-4Authors
		R. Bachmann-Gagescu, University of Washington School of Medicine Division of Medical Genetics, Department of Medicine Seat...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2662228</comments>
            <pubDate>Wed, 29 Jul 2009 07:01:10 +0100</pubDate>
            <guid isPermaLink="false">2662228</guid>        </item>
        <item>
            <title>Long-term needs of adult patients with organic acidaemias: outcome and prognostic factors</title>
            <link>http://www.medworm.com/index.php?rid=2644183&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm5h2r7362m776428%2F</link>
            <description>Conclusions: The approach to adult patients with OA has to be multidisciplinary, with the clinician and dietician as the core of the
 team, but with the collaboration of clinical nurses specialists, social workers and other specialist services and the support
 of a biochemical and molecular laboratory.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-1191-12Authors
		E. Martín-Hernández, UCLH Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery London UKP. J. Lee, UCLH Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery London UKA. Micciche, UCLH Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery London UKS. Grunewald, Great Ormond Street Hospital, UCL Department for Metabolic Medi...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2644183</comments>
            <pubDate>Sat, 25 Jul 2009 04:33:59 +0100</pubDate>
            <guid isPermaLink="false">2644183</guid>        </item>
        <item>
            <title>Metabolic phenotypes of phenylketonuria. Kinetic and molecular evaluation of the Blaskovics protein loading test</title>
            <link>http://www.medworm.com/index.php?rid=2633239&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr637nn8681v0845w%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;
 Background: As part of the German Collaborative Study of Children Treated for Phenylketonuria (PKU), a three-day protein loading test
 was applied to children at 6&amp;nbsp;months of age. This load elicits three principal types of blood phenylalanine (Phe) response,
 with types I and III clinically corresponding to classic PKU and mild hyperphenylalaninaemia not requiring diet (MHP), respectively.
 An intermediate type II, clinically corresponding to mild PKU, is characterized by early decline of blood Phe from above 1200
 μmol/L down to levels between 600 and 1200 μmol/L at 72&amp;nbsp;h. Aims: Unbiased classification and kinetic and molecular characterization of the intermediate Phe response; estimation of phenotypic
 variability of Phe disposal.Method: A kinetic model wit...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2633239</comments>
            <pubDate>Tue, 21 Jul 2009 00:09:00 +0100</pubDate>
            <guid isPermaLink="false">2633239</guid>        </item>
        <item>
            <title>In response to van Spronsen et al (2009) Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU (J Inherit Metab Dis 32: 27–31)</title>
            <link>http://www.medworm.com/index.php?rid=3099277&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhht7348v17746462%2F</link>
            <description>In response to van Spronsen et al (2009) Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU (J Inherit Metab Dis 32: 27–31)
	Content Type Journal ArticleCategory LETTER TO THE EDITORDOI 10.1007/s10545-009-9959-8Authors
		Alberto Ponzone, University of Torino Department of Pediatrics Torino ItalyAlessandro Mussa, University of Torino Department of Pediatrics Torino ItalyFrancesco Porta, University of Torino Department of Pediatrics Torino Italy
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955
	
		Journal Volume Volume 32
	
		Journal Issue Volume 32, Number 4 / August, 2009 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3099277</comments>
            <pubDate>Tue, 21 Jul 2009 00:08:59 +0100</pubDate>
            <guid isPermaLink="false">3099277</guid>        </item>
        <item>
            <title>In response to van Spronsen et al (2009) Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU (J Inherit Metab Dis 32: 27–31)</title>
            <link>http://www.medworm.com/index.php?rid=2633241&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhht7348v17746462%2F</link>
            <description>Content Type Journal ArticleCategory LETTER TO THE EDITORDOI 10.1007/s10545-009-9959-8Authors
		Alberto Ponzone, University of Torino Department of Pediatrics Torino ItalyAlessandro Mussa, University of Torino Department of Pediatrics Torino ItalyFrancesco Porta, University of Torino Department of Pediatrics Torino Italy
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2633241</comments>
            <pubDate>Tue, 21 Jul 2009 00:08:59 +0100</pubDate>
            <guid isPermaLink="false">2633241</guid>        </item>
        <item>
            <title>Gender dimorphism in siblings with schizophrenia-like psychosis due to Niemann-Pick disease type C</title>
            <link>http://www.medworm.com/index.php?rid=2633240&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2p25385q66n1j854%2F</link>
            <description>We describe the differential presentation of schizophrenia-like psychosis in two siblings with the ‘variant’ biochemical presentation
 of adult Niemann-Pick disease type C. The male sibling presented with psychosis at age 16&amp;nbsp;years and cognitive and motor disturbance
 at age 25&amp;nbsp;years, whereas his elder sister, sharing the same mutation but showing less severe biochemical, neuroimaging and
 ocular motor parameters, presented with a similar schizophrenia-like illness with associated cognitive and motor disturbance
 at age 31&amp;nbsp;years. Their illness onset, course and response to treatment mirrors the sex dimorphism seen in schizophrenia, and
 is suggestive of an interaction between the neurobiology of their metabolic disorder and sex differences in neurodevelopment.
 
	Content ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2633240</comments>
            <pubDate>Tue, 21 Jul 2009 00:08:59 +0100</pubDate>
            <guid isPermaLink="false">2633240</guid>        </item>
        <item>
            <title>Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)</title>
            <link>http://www.medworm.com/index.php?rid=2605001&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgw6480557024x034%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a progressive, multisystemic disease caused by a deficiency of
 iduronate-2-sulfatase. Patients with the severe form of the disease have cognitive impairment and typically die in the second
 decade of life. Patients with the less severe form do not experience significant cognitive involvement and may survive until
 the fifth or sixth decade of life. We studied the relationship of both severity of MPS II and the time period in which patients
 died with age at death in 129 patients for whom data were entered retrospectively into HOS (Hunter Outcome Survey), the only
 large-scale, multinational observational study of patients with MPS II. Median age at death was significantly lower in patients
 with cognitive invo...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2605001</comments>
            <pubDate>Tue, 14 Jul 2009 11:09:34 +0100</pubDate>
            <guid isPermaLink="false">2605001</guid>        </item>
        <item>
            <title>Inherited disorders in the conversion of methionine to homocysteine</title>
            <link>http://www.medworm.com/index.php?rid=2592839&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk53w2j6324884p1n%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;During the last decade much important new information relating to the metabolic pathway from methionine to homocysteine has
 been gained. Interest has been stimulated by the discovery of two novel disorders, glycine N-methyltransferase deficiency and S-adenosylhomocysteine hydrolase deficiency. Another disorder in this pathway, methionine adenosyltransferase deficiency, has
 been increasingly detected, thanks to the expansion of newborn screening programmes by tandem mass spectrometry technology.
 These significant steps allow important insight into the pathogenesis of these three disorders, as well as into the mechanisms
 of damage to various organs (liver, brain, muscle) and point to the relevance of these disorders for crucial biological processes
 such as methylation...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592839</comments>
            <pubDate>Thu, 09 Jul 2009 12:32:56 +0100</pubDate>
            <guid isPermaLink="false">2592839</guid>        </item>
        <item>
            <title>Insulin-resistant hyperglycaemia complicating neonatal onset of methylmalonic and propionic acidaemias</title>
            <link>http://www.medworm.com/index.php?rid=2592841&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjm70269207h8n335%2F</link>
            <description>Conclusion: Insulin-resistant hyperglycaemia complicating neonatal onset of methylmalonic and propionic acidaemias is probably a marker
 of a serious disease. One patient with this complication survived after a strong reduction of glucose administration. Even
 if this is probably only a partial intervention, we hypothesize that in this situation a reduction of glucose administration
 can reduce almost the risk of persistent hyperglycaemia. Further studies are required to confirm our hypothesis.
 
	Content Type Journal ArticleCategory ONLINE REPORTDOI 10.1007/s10545-009-1141-9Authors
		L. Filippi, ‘A. Meyer’ University Children’s Hospital Neonatal Intensive Care Unit, Department of Critical Care Medicine viale Pieraccini, 24 50134 Florence ItalyE. Gozzini, ‘A. Meyer’ University Ch...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592841</comments>
            <pubDate>Thu, 09 Jul 2009 12:32:54 +0100</pubDate>
            <guid isPermaLink="false">2592841</guid>        </item>
        <item>
            <title>Serum phenylalanine concentrations in patients post trauma and burn correlate to neopterin concentrations</title>
            <link>http://www.medworm.com/index.php?rid=2592840&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft0553028m5203781%2F</link>
            <description>Content Type Journal ArticleCategory LETTER TO THE EDITORDOI 10.1007/s10545-009-9960-2Authors
		S. Scholl-Buergi, Biocenter, Innsbruck Medical University Department of Pediatrics Innsbruck AustriaG. Neurauter, Innsbruck Medical University Division of Biological Chemistry, Biocenter Fritz Pregl Strasse 3 6020 Innsbruck AustriaD. Karall, Biocenter, Innsbruck Medical University Department of Pediatrics Innsbruck AustriaD. Fuchs, Innsbruck Medical University Division of Biological Chemistry, Biocenter Fritz Pregl Strasse 3 6020 Innsbruck Austria
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592840</comments>
            <pubDate>Thu, 09 Jul 2009 12:32:54 +0100</pubDate>
            <guid isPermaLink="false">2592840</guid>        </item>
        <item>
            <title>Retinitis pigmentosa and mucopolysaccharidosis type II: an extremely attenuated phenotype</title>
            <link>http://www.medworm.com/index.php?rid=2592842&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F202613115662p3x7%2F</link>
            <description>Content Type Journal ArticleCategory IMAGES IN METABOLIC MEDICINEDOI 10.1007/s10545-009-1204-yAuthors
		Y. Suzuki, Gifu University Graduate School of Medicine Department of Pediatrics and Medical Education Development Center Yanagido 1-1 Gifu 501-1194 JapanA. Aoyama, Gifu University Graduate School of Medicine Department of Ophthalmology Gifu JapanT. Kato, Gifu University Graduate School of Medicine Department of Pediatrics and Medical Education Development Center Yanagido 1-1 Gifu 501-1194 JapanN. Shimozawa, Gifu University Division of Genomic Research, Life Science Research Center Gifu JapanT. Orii, Orii Clinic Gifu Japan
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592842</comments>
            <pubDate>Thu, 09 Jul 2009 12:32:52 +0100</pubDate>
            <guid isPermaLink="false">2592842</guid>        </item>
        <item>
            <title>Experience with the treatment of argininosuccinic aciduria during pregnancy</title>
            <link>http://www.medworm.com/index.php?rid=2592843&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9661l72635611115%2F</link>
            <description>We present the details of the management and the outcome of a pregnancy of a woman affected with argininosuccinic aciduria.
 Management with a closely monitored, protein-restricted diet, supplemented with L-arginine, resulted in the birth of a healthy
 infant boy and an uneventful perinatal course for the mother.
 
	Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10545-009-1145-5Authors
		L. Reid, Centre hospitalier universitaire de Sherbrooke Service de génétique médicale 3001, 12th Avenue Nord Sherbrooke Québec J1H 5N4 CanadaÉ. Perreault, Centre hospitalier universitaire de Sherbrooke Service de génétique médicale 3001, 12th Avenue Nord Sherbrooke Québec J1H 5N4 CanadaG. Lafrance, Centre hospitalier universitaire de Sherbrooke Service de génétique médicale 3001,...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592843</comments>
            <pubDate>Thu, 09 Jul 2009 12:32:51 +0100</pubDate>
            <guid isPermaLink="false">2592843</guid>        </item>
        <item>
            <title>Danon disease: Case report and detection of new mutation</title>
            <link>http://www.medworm.com/index.php?rid=2592844&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1mp4173123804r30%2F</link>
            <description>We report a male patient with skeletal myopathy, mental retardation, and massive hypertrophic obstructive cardiomyopathy
 necessitating heart transplantation. Immunohistochemistry of skeletal muscle and leukocytes, western blot analysis of leukocytes
 and cardiac muscle, flow cytometry, and DNA sequencing were performed. Muscle biopsy revealed autophagic vacuolar myopathy
 and lack of immunohistochemically detectable LAMP-2. Diagnosis of Danon disease was confirmed by western blot analysis of
 myocardial tissue and peripheral blood sample of the patient showing deficiency of LAMP-2 in myocardium and leukocytes. Moreover,
 absence of LAMP-2 in lymphocytes, monocytes and granulocytes was shown by flow cytometric analysis. Genetic analysis of the
 LAMP2 gene revealed a novel 1-bp deletion at ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592844</comments>
            <pubDate>Thu, 09 Jul 2009 12:32:50 +0100</pubDate>
            <guid isPermaLink="false">2592844</guid>        </item>
        <item>
            <title>Sleep-related breathing in children with mucopolysaccharidosis</title>
            <link>http://www.medworm.com/index.php?rid=2559434&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg332710767w83563%2F</link>
            <description>Conclusions: Children with MPS have a high prevalence of significant OSA and thus should be carefully screened for OSA using full polysomnography
 and treated accordingly.
 
	Content Type Journal ArticleCategory ORIGINAL ARTICLEDOI 10.1007/s10545-009-1170-4Authors
		A. Nashed, The Hospital for Sick Children Toronto Ontario CanadaS. Al-Saleh, The Hospital for Sick Children Toronto Ontario CanadaJ. Gibbons, The Hospital for Sick Children Toronto Ontario CanadaI. MacLusky, The Children’s Hospital of Eastern Ontario Ottawa Ontario CanadaJ. MacFarlane, University of Toronto Department of Paediatrics and Psychiatry Toronto Ontario CanadaA. Riekstins, The Hospital for Sick Children Toronto Ontario CanadaJ. Clarke, The Hospital for Sick Children Toronto Ontario CanadaI. Narang, The Hospital for ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2559434</comments>
            <pubDate>Mon, 29 Jun 2009 08:24:13 +0100</pubDate>
            <guid isPermaLink="false">2559434</guid>        </item>
        <item>
            <title>Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs</title>
            <link>http://www.medworm.com/index.php?rid=2559435&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0250912230732ng1%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Intravenous enzyme replacement therapy with recombinant human α-l-iduronidase (rhIDU) is used weekly to treat mucopolysaccharidosis (MPS) I. We tested continuous administration of rhIDU at
 two dosing levels (0.58&amp;nbsp;mg/kg per week and 2&amp;nbsp;mg/kg per week) in MPS I dogs, and compared the efficacy of continuous infusion
 with the clinically used 0.58&amp;nbsp;mg/kg weekly three-hour infusion. Peak plasma concentrations of rhIDU were much higher in weekly-treated
 dogs (mean 256 units/ml) than steady-state concentrations in dogs treated with continuous infusion (mean 1.97 units/ml at
 0.58&amp;nbsp;mg/kg per week; 8.44 units/ml at 2&amp;nbsp;mg/kg per week). Dogs receiving continuous IV rhIDU, even at a higher (2&amp;nbsp;mg/kg per
 week) dose, had consistently lower iduronidase leve...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2559435</comments>
            <pubDate>Mon, 29 Jun 2009 08:24:07 +0100</pubDate>
            <guid isPermaLink="false">2559435</guid>        </item>
        <item>
            <title>Orotic aciduria and uridine monophosphate synthase: A reappraisal</title>
            <link>http://www.medworm.com/index.php?rid=2559436&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy27741337300r42h%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Three subtypes of hereditary orotic aciduria are described in the literature, all related to deficiencies in uridine monophosphate
 synthase, the multifunctional enzyme that contains both orotate: pyrophosphoryl transferase and orotidine monophosphate decarboxylase
 activities. The type of enzyme defect present in the subtypes has been re-examined by steady-state modelling of the relative
 outputs of the three enzymic products, uridine monophosphate, urinary orotic acid and urinary orotidine. It is shown that
 the ratio of urinary outputs of orotidine to orotate provides a means of testing for particular forms of enzyme defect. It
 is confirmed that the type I defect is caused by loss of uridine monophosphate synthase activity. Cells and tissue of type
 I cases have a r...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2559436</comments>
            <pubDate>Mon, 29 Jun 2009 08:24:00 +0100</pubDate>
            <guid isPermaLink="false">2559436</guid>        </item>
        <item>
            <title>IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: A case report</title>
            <link>http://www.medworm.com/index.php?rid=2559437&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp414491427m65k28%2F</link>
            <description>We present the case of a 65-year-old woman with extensive GD I associated with IgM
 MGUS, in whom enzyme replacement therapy succeeded in eradicating the monoclonal component. This observation further supports
 the idea that enzyme replacement therapy decreases the chronic antigenic stimulation responsible for gammopathies in Gaucher
 disease.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-1207-8Authors
		C. Martinez-Redondo, Hospital Universitario J.M. Morales Meseguer Hematology and Clinical Oncology Unit Marqués de los Vélez s/n 30008 Murcia SpainF. J. Ortuño, Hospital Universitario J.M. Morales Meseguer Hematology and Clinical Oncology Unit Marqués de los Vélez s/n 30008 Murcia SpainM. L. Lozano, Hospital Universitario J.M. Morales Meseguer Hematolo...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2559437</comments>
            <pubDate>Mon, 29 Jun 2009 08:23:52 +0100</pubDate>
            <guid isPermaLink="false">2559437</guid>        </item>
        <item>
            <title>Long-term neurodevelopmental effects of early detection and treatment in a 6-year-old patient with argininaemia diagnosed by newborn screening</title>
            <link>http://www.medworm.com/index.php?rid=2559438&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff74767u337l14r8u%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Newborn screening makes possible the early identification and treatment of asymptomatic ARG1-deficient patients; however,
 it is unknown whether early intervention prevents neurological insults. We identified a full-term Hispanic male infant with
 argininaemia by newborn screening with a serum arginine of 327&amp;nbsp;µmol/L (reference values 0–140); ARG1 was undetectable on enzyme
 assay. Sequence analysis of ARG1 revealed a heterozygous nonsense mutation, c.223A&amp;gt;T (p.K75X), and a novel heterozygous missense variant, c.425G&amp;gt;A (p.G142E).
 Dietary protein restriction began from age 3&amp;nbsp;months, with addition of sodium benzoate at 4&amp;nbsp;months, and carnitine from 14&amp;nbsp;months.
 For the past 6&amp;nbsp;years, his serum arginine concentrations were maintained between 2...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2559438</comments>
            <pubDate>Mon, 29 Jun 2009 08:23:45 +0100</pubDate>
            <guid isPermaLink="false">2559438</guid>        </item>
        <item>
            <title>Preface</title>
            <link>http://www.medworm.com/index.php?rid=2549964&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcq8218012u724227%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/BF03047364Authors
		G. M. AddisonR. A. ChalmersR. J. PollitP. DivryR. A. Harkness
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955
	
		Journal Volume Volume 7
	
		Journal Issue Volume 7, Supplement 1 / March, 1984 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549964</comments>
            <pubDate>Fri, 26 Jun 2009 06:29:37 +0100</pubDate>
            <guid isPermaLink="false">2549964</guid>        </item>
        <item>
            <title>The differential diagnosis of dicarboxylic aciduria</title>
            <link>http://www.medworm.com/index.php?rid=2549965&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu1317nu7vq448x85%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Various types of dicarboxylic aciduria are known, most of them are accompanied by non-ketotic hypoglycaemia. For the differential
 diagnosis of these conditions several methods of investigation have been used: (1) analysis of urinary organic acids in both
 native and hydrolysed samples, (2) analysis of free and esterified carnitine, the latter by means of chromatographic separation
 and identification of acyl moieties, (3) analysis of plasma organic acids, including the so-called free fatty acids, (4) a
 prolonged fasting test with serial measurements of the aforementioned parameters and close monitoring of the blood glucose
 and (5) an oral loading test with medium chain triglycerides accompanied by the same measurements as those named in item (4).
 
 So far differenti...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549965</comments>
            <pubDate>Fri, 26 Jun 2009 06:29:31 +0100</pubDate>
            <guid isPermaLink="false">2549965</guid>        </item>
        <item>
            <title>Gas chromatography-mass spectrometry (GC-MS) diagnosis of two cases of medium chain Acyl-CoA dehydrogenase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2549966&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb158300200j45436%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Two patients with hypoketotic hypoglycaemia and dicarboxylic aciduria are described. Studies of their urinary organic acids
 by gas chromatography-mass spectrometry (GC-MS) showed an excretion of dicarboxylic acids (adipic suberic and sebacic acids),
 unsaturated dicarboxylic acids (cis-octenedioic and decenedioic acids), 5-hydroxyhexanoic acid, hexanoyl-glycine and suberylglycine. Deficiency of the medium
 chain acyl-CoA dehydrogenase (MCAD) in fibroblasts was documented for both children. Despite a similar presentation (hypoglycaemic
 coma), organic acid profile (dicarboxylic aciduria and suberylglycine excretion) and enzyme deficiency (MCAD), they did not
 respond similarly to glucose infusion.
 
	Content Type Journal ArticleCategory Dicarboxylic Acidurias And Acyl-C...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549966</comments>
            <pubDate>Fri, 26 Jun 2009 06:29:24 +0100</pubDate>
            <guid isPermaLink="false">2549966</guid>        </item>
        <item>
            <title>Carnitine metabolism and inborn errors</title>
            <link>http://www.medworm.com/index.php?rid=2549967&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft4l85847r8h46249%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Current knowledge of the metabolic role, biosynthesis, cellular uptake, excretion and turnover of carnitine is reviewed. The
 clinical spectrum and possible aetiology of the primary muscle and primary systemic carnitine deficiency syndromes are considered
 and the various genetic defects of intermediary metabolism which can give rise to secondary carnitine deficiency are indicated.
 
	Content Type Journal ArticleCategory Dicarboxylic Acidurias And Acyl-Coa Dehydrogenase DeficienciesDOI 10.1007/BF03047372Authors
		A. G. Engel, Mayo Clinic and Mayo Foundation Neuromuscular Research Laboratory, Department of Neurology 55905 Rochester MN USAC. J. Rebouche, Mayo Clinic and Mayo Foundation Neuromuscular Research Laboratory, Department of Neurology 55905 Rochester MN USA
	

	
...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549967</comments>
            <pubDate>Fri, 26 Jun 2009 06:29:18 +0100</pubDate>
            <guid isPermaLink="false">2549967</guid>        </item>
        <item>
            <title>Long term outcome of organic acidurias: Survey of 105 French cases (1967–1983)</title>
            <link>http://www.medworm.com/index.php?rid=2549968&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa4501612q2222144%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The French experience in the long term follow-up of 105 cases of organic aciduria (45 maple syrup urine disease, 12 isovaleric
 acidaemia, 19 propionic acidaemia, 24 methylmalonic aciduria and some rare allied disorders) is reported. Main conclusions
 drawn from this survey are the poor overall prognosis and the slow improvement in the outcome of such disorders over the last
 15 years. In MSUD, while early diagnosis and early management remain a basic requirement, intellectual development did not
 improve as much as expected. In propionic and methylmalonic acidaemia modern treatment does not prevent a fatal outcome in
 the classical neonatal forms. It should be also emphasized that in the rare cases where a coenzyme deficiency has been demonstrated,
 vitamin therapy is ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549968</comments>
            <pubDate>Fri, 26 Jun 2009 06:29:11 +0100</pubDate>
            <guid isPermaLink="false">2549968</guid>        </item>
        <item>
            <title>Hudson memorial lecture</title>
            <link>http://www.medworm.com/index.php?rid=2549969&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr254480685190150%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Therapeutic guidelines have been obtained from a restrospective review of 41 patients affected with organic acidaemias, 16
 patients with neonatal maple syrup urine disease (MSUD), 11 methylmalonic acidaemia, (MMA) seven propionic acidaemias (PA)
 and seven isovaleric acidaemias (IVA), and by comparing this personal series with similar reported cases. The emergency treatment
 of these organic acidurias in the neonate has to main goals: toxin removal and anabolism. Anabolism is always promoted by
 early diet therapy. The best method of toxin removal depends on the nature of the defect; peritoneal dialysis with exchange
 transfusions or multiple or prolonged exchange transfusions in MSUD and in PA, diuresis and exchange transfusions in MMA and
 glycine supplementation in ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549969</comments>
            <pubDate>Fri, 26 Jun 2009 06:29:04 +0100</pubDate>
            <guid isPermaLink="false">2549969</guid>        </item>
        <item>
            <title>Glutaric acidaemia type II (multiple Acyl-Coa dehydrogenation deficiency)</title>
            <link>http://www.medworm.com/index.php?rid=2549970&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9438t53177513q22%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The clinical and biochemical phenotype of glutaric acidaemia type II (GAII) has led to the suggestion that the defect in the
 disorder affects electron transfer from primary FAD-containing dehydrogenases into the respiratory chain. Two proteins are
 involved in this process, i.e. electron transfer flavoprotein (ETF) and ETF dehydrogenase, an iron-sulphur flavoprotein with
 a distinctive EPR signal. Reliable catalytic assays for these proteins are not available, but both proteins have been purified
 and antisera against them prepared in rabbits.
 
 SDS-PAG electrophoresis of liver mitochondrial membranes from a GAII infant with congenital anomalies, locating ETF dehydrogenase
 with specific antiserum, showed no cross-reactive material. EPR of the same membranes showed a ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549970</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:58 +0100</pubDate>
            <guid isPermaLink="false">2549970</guid>        </item>
        <item>
            <title>Fatty Acyl-CoA dehydrogenase deficiency: Enzyme measurement and studies on alternative metabolism</title>
            <link>http://www.medworm.com/index.php?rid=2549971&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq071074m16q07334%2F</link>
            <description>Abstact&amp;nbsp;&amp;nbsp;Fatty acyl-CoA dehydrogenase deficiencies are defined as disorders of the metabolism of straight chain acyl-CoA esters at
 the level of short chain acyl-CoA, general (medium chain) acyl-CoA and long chain acyl-CoA dehydrogenases. Patients with proven
 or indicated defects in either general (medium chain) or long chain acyl-CoA dehydrogenase have been reported.
 
 In recent years assays for the enzymatic diagnosis in cells, especially cultured skin fibroblasts, from such patients have
 been developed. The different methods are reviewed. The urinary excretion profile of organic acids from patients with fatty
 acyl-CoA dehydrogenase deficiencies are characterized by the presence of different compounds originating from the primary
 accumulated acyl-CoA ester(s). The most imp...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549971</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:51 +0100</pubDate>
            <guid isPermaLink="false">2549971</guid>        </item>
        <item>
            <title>Symptoms and signs in organic acidurias</title>
            <link>http://www.medworm.com/index.php?rid=2549972&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F80k2353170032k53%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Organic acidaemias can present with a wide variety of signs and symptoms. A survey of the clinical presentation of the organic
 acidurias shows that single symptoms are not characteristic or diagnostic. Clinical awareness coupled with appropriate laboratory
 investigation is required for the correct diagnosis to be reached.
 
	Content Type Journal ArticleCategory Clinical Aspects: Management And OutcomeDOI 10.1007/BF03047369Authors
		N. J. Brandt, University Department of Pediatrics, Rigshospitalet Section of Clinical Genetics Copenhagen Denmark
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955
	
		Journal Volume Volume 7
	
		Journal Issue Volume 7, Supplement 1 / March, 1984 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549972</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:44 +0100</pubDate>
            <guid isPermaLink="false">2549972</guid>        </item>
        <item>
            <title>Prenatal diagnosis of the organic acidurias</title>
            <link>http://www.medworm.com/index.php?rid=2549973&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy2130673ng2vv6t3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Prenatal diagnosis for the genetic counselling of families at risk for having children with the life-threatening organic acidurias
 is advancing rapidly. The two major approaches to prenatal diagnosis are the assay for deficient activity of the enzymes in
 cultured amniocytes and the measurement of increased concentrations of the organic acids in the amniotic fluid. The latter,
 when done by stable isotope dilution analysis, is rapid, relatively inexpensive and very reliable.
 
	Content Type Journal ArticleCategory Clinical Aspects: Management And OutcomeDOI 10.1007/BF03047368Authors
		L. Sweetman, University of California Department of Pediatrics M-009 92093 San Diego, La Jolla CA USA
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549973</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:37 +0100</pubDate>
            <guid isPermaLink="false">2549973</guid>        </item>
        <item>
            <title>The management and long term outcome of organic acidaemias</title>
            <link>http://www.medworm.com/index.php?rid=2549974&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff36854352gq1l217%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We review the outcome of patients with maple syrup urine disease (14 classical patients and three variants), biotinidase deficiency
 (two patients) and non-cofactor-responsive variants of methylmalonic acidaemia (eight patients), propionic acidaemia (eight
 patients) and isolated 3-methylcrotonyl CoA carboxylase deficiency (three patients). Their survival, growth, intellectual
 development and other clinical problems are analysed. With the exception of isolated 3-methylcrotonyl CoA carboxylase deficiency
 the outcome of patients with disorders that are not cofactor responsive is disappointing. Twelve patients have died (five
 maple syrup urine disease, two methylmalonic acidaemia, five propionic acidaemia) and many of the survivors are developmentally
 retarded. The out...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549974</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:30 +0100</pubDate>
            <guid isPermaLink="false">2549974</guid>        </item>
        <item>
            <title>Mitochondrial oxidative phosphorylation and respiratory chain: Review</title>
            <link>http://www.medworm.com/index.php?rid=2549975&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx23u346xt6207650%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Basic events concerning oxidative phosphorylation, i.e. the synthesis of ATP at the expense of respired oxygen at the level
 of mitochondria are described. Our knowledge concerning the functioning of respiratory chain, its structure, organization
 and topology inside the inner membrane of mitochondria has considerably improved in recent years. A central question — how
 does the respiratory chain cooperate with ATP-synthetase, also embedded in the inner membrane, to bring about the oxidative
 phosphorylation of ADP to ATP — has been one of the most challenging and difficult problems in biochemical research. The chemiosmotic
 hypothesis proposed by the British biochemist Peter Mitchell appears best in describing the basic events of the recovery of
 the redox energy li...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549975</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:24 +0100</pubDate>
            <guid isPermaLink="false">2549975</guid>        </item>
        <item>
            <title>Animal models for dicarboxylic aciduria</title>
            <link>http://www.medworm.com/index.php?rid=2549976&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe411646112401m32%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Four compounds, 2[5(4-chlorophenyl)pentyl] oxirane-2-carboxylate (POCA), pent-4-enoate, hypoglycin and valproate, which are
 hypoglycaemic in fasted animals and form unusual acyl-CoA estersin vivo, inhibit mitochondrial β-oxidation by different mechanisms. POCA, hypoglycin and valproate are known to cause dicarboxylic
 aciduria. Saturated dicarboxylic acids are thought to be derived from long chain fatty acids by peroxisomal β-oxidation when
 mitochondrial β-oxidation is severely impaired. The use of these inhibitors provides animal models of dicarboxylic aciduria
 found in some inborn errors of metabolism.
 
	Content Type Journal ArticleCategory Dicarboxylic Acidurias And Acyl-CoA Dehydrogenase DeficienciesDOI 10.1007/BF03047375Authors
		H. S. A. Sherratt, Universit...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549976</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:17 +0100</pubDate>
            <guid isPermaLink="false">2549976</guid>        </item>
        <item>
            <title>Mitochondrial myopathies: Disorders of the respiratory chain and oxidative phosphorylation</title>
            <link>http://www.medworm.com/index.php?rid=2549977&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw65lu9pg06789433%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mitochondrial myopathies are a clinical condition characterized by muscle weakness and fatigue in which the primary defect
 is localized at the level of the mitochondria. Microscopic examination shows accumulations of mitochondria at the fibre periphery
 (ragged red fibres) and in some cases mitochondrial paracrystalline inclusions. The spectrum of different mitochondrial defects
 so far described is reviewed and data from cases investigated in this laboratory are described. The first case was a 17-year-old
 boy with a multisystem disorder whose muscle mitochondria showed low respiratory activity with all substrates, which doubled
 in the presence of uncouples Further investigation showed that the mitochondrial ATPase activity was only 6 % of normal. The
 next cases wer...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549977</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:10 +0100</pubDate>
            <guid isPermaLink="false">2549977</guid>        </item>
        <item>
            <title>4-Hydroxybutyric aciduria: A new inborn error of metabolism. I. Clinical review</title>
            <link>http://www.medworm.com/index.php?rid=2549978&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdj88191622758m56%2F</link>
            <description>Content Type Journal ArticleCategory A New Disorder: 4-Hydroxybutyric AciduriaDOI 10.1007/BF03047381Authors
		D. Rating, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.F. Hanefeld, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.H. Siemes, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.J. Kneer, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.C. Jakobs, Academic Hospital of the Free University of Amsterdam Department of Pediatrics De Boelelaan 1117 1007 MB Amsterdam The NetherlandsM. Hermier, Hôpital Debro...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549978</comments>
            <pubDate>Fri, 26 Jun 2009 06:28:03 +0100</pubDate>
            <guid isPermaLink="false">2549978</guid>        </item>
        <item>
            <title>Organic acids in urine of patients with congenital lactic acidoses: An aid to differential diagnosis</title>
            <link>http://www.medworm.com/index.php?rid=2549979&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv917r5572rl80252%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The differential diagnosis of patients with apparent congenital lactic acidoses poses one of the most intractable problems
 in the study of patients with disorders of organic acid metabolism. An outline of the factors leading to a lactic acidosis,
 particularly in infants and young children, together with a brief review of the known causes of congenital lactic acidosis,
 are presented. Quantitative examination of the organic acids excreted by patients with proven enzyme deficiencies causing
 congenital lactic acidosis has demonstrated the characteristic patterns that are associated with specific disorders of this
 kind. After exclusion of uninherited, acquired and secondary metabolic causes of lactic acidosis, these quantitative patterns
 of organic acid excretion, toge...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549979</comments>
            <pubDate>Fri, 26 Jun 2009 06:27:56 +0100</pubDate>
            <guid isPermaLink="false">2549979</guid>        </item>
        <item>
            <title>Lactic acidaemia</title>
            <link>http://www.medworm.com/index.php?rid=2549980&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcn14qj00754v0l58%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Congenital childhood lactic acidaemia is a poorly understood group of genetic diseases. The most common underlying inherited
 defect encountered in this group is deficiency of the pyruvate dehydrogenase complex. Of 23 cases we have diagnosed, 18 have
 a deficiency in the first component of the complex, the E1 decarboxylase, while the other five have multipleα-keto acid dehydrogenase deficiency due to a defect in lipoamide dehydrogenase. In addition to the lactic acidosis associated
 with pyruvate decarboxylase deficiency, ten of the cases showed evidence of facial dysmorphism consisting of a narrow head,
 wide nasal bridge and flared nostrils or gross microcephaly. Two further patients had agenesis of the corpus callosum. Isolated
 pyruvate carboxylase deficiency was f...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549980</comments>
            <pubDate>Fri, 26 Jun 2009 06:27:49 +0100</pubDate>
            <guid isPermaLink="false">2549980</guid>        </item>
        <item>
            <title>Pyruvate carboxylase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2549981&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu2v54253hmh3086l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The causes of congenital lactic acidaemia are outlined. Isolated pyruvate carboxylase deficiency is reviewed in detail with
 a report of a recent case and a discussion of the biochemical consequences. Other causes of defective pyruvate carboxylation
 are described, particularly the combined carboxylase defects.
 
	Content Type Journal ArticleCategory Disorders Of The Respiratory Chain And The Lactic AcidaemiasDOI 10.1007/BF03047379Authors
		K. Bartlett, University of Newcastle upon Tyne Department of Clinical Biochemistry and Metabolic Medicine NE1 7R U Newcastle upon Tyne UKH. K. Ghneim, University of Newcastle upon Tyne Department of Clinical Biochemistry and Metabolic Medicine NE1 7R U Newcastle upon Tyne UKJ. -H. Stirk, University of Newcastle upon Tyne Department o...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549981</comments>
            <pubDate>Fri, 26 Jun 2009 06:27:41 +0100</pubDate>
            <guid isPermaLink="false">2549981</guid>        </item>
        <item>
            <title>4-Hydroxybutyric aciduria: A new inborn error of metabolism. II. Biochemical findings</title>
            <link>http://www.medworm.com/index.php?rid=2549982&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbx217183873k2442%2F</link>
            <description>Content Type Journal ArticleCategory A New Disorder: 4-Hydroxybutyric AciduriaDOI 10.1007/BF03047382Authors
		C. Jakobs, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.J. Kneer, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.D. Rating, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.F. Hanefeld, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.R.P. Divry, Hôpital Debrousse Laboratoire de Biochimie 29 rue Soeur Bouvier 69322 Lyon, Cedex 5 FranceM. Hermier, Hôpital Debrousse Laboratoire de Biochimie 29 rue Soe...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549982</comments>
            <pubDate>Fri, 26 Jun 2009 06:27:34 +0100</pubDate>
            <guid isPermaLink="false">2549982</guid>        </item>
        <item>
            <title>4-Hydroxybutyric aciduria: A new inborn error of metabolism. III. Enzymology and inheritance</title>
            <link>http://www.medworm.com/index.php?rid=2549983&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft1451x8101808721%2F</link>
            <description>Content Type Journal ArticleCategory A New Disorder: 4-Hydroxybutyric AciduriaDOI 10.1007/BF03047383Authors
		K. M. Gibson, University of California Departments of Chemistry, Medicine and Pediatrics 92093 San Diego, La Jolla CA USAI. Jansen, University of California Departments of Chemistry, Medicine and Pediatrics 92093 San Diego, La Jolla CA USAL. Sweetman, University of California Departments of Chemistry, Medicine and Pediatrics 92093 San Diego, La Jolla CA USAW. L. Nyhan, University of California Departments of Chemistry, Medicine and Pediatrics 92093 San Diego, La Jolla CA USAD. Rating, Free University of Berlin Department of Pediatrics Kaiserin Auguste Victoria Haus, Heubnerweg 6 D-1000 Berlin 19 G.F.RC. Jakobs, Academic Hospital of the Free University of Amsterdam Department of P...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2549983</comments>
            <pubDate>Fri, 26 Jun 2009 06:27:28 +0100</pubDate>
            <guid isPermaLink="false">2549983</guid>        </item>
        <item>
            <title>An unusual genetic variant in the MOCS1 gene leads to complete missplicing of an alternatively spliced exon in a patient with molybdenum cofactor deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2500277&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0797861712t48658%2F</link>
            <description>We report an unusual mutation in the MOCS1 gene associated with a relatively mild clinical phenotype, in a patient who presented with normal uric acid (UA) levels
 in plasma. We also report a new MOCS1 mRNA splice variant in the 5′ region of the gene. MOCS1 genomic DNA and cDNA from peripheral blood leukocytes were sequenced. MOCS1 mRNA splice variants were amplified with fluorescently
 labelled primers and quantitated. A novel homozygous mutation MOCS1c.1165+6T &amp;gt; C in intron 9 resulting in miss-splicing of exon 9 was found. Multiple alternatively spliced MOCS1 transcripts have been previously reported. A new MOCS1 transcript in the 5′ – exon 1 region was identified in both patient and controls. This new transcript derived from the Larin
 variant and lacked exon 1&amp;nbsp;d.
 
	Conte...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2500277</comments>
            <pubDate>Sat, 20 Jun 2009 06:06:13 +0100</pubDate>
            <guid isPermaLink="false">2500277</guid>        </item>
        <item>
            <title>Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) as a cause of liver disease in infants in the UK</title>
            <link>http://www.medworm.com/index.php?rid=2500278&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc441542623817731%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Citrin deficiency is a disorder with two phenotypes: neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD),
 and adult-onset type II citrullinaemia (CTLN2). NICCD presents in the first few weeks of life with prolonged cholestasis and
 metabolic abnormalities including aminoacidaemia (notably citrulline, tyrosine, threonine, arginine and methionine) and galactosuria.
 Symptoms resolve within the first year of life, thus making a diagnosis difficult after this time. Although patients subsequently
 remain generally healthy, some may develop more severe symptoms of CTLN2, characterized by neurological changes, one or more
 decades later. To date more than 400 cases have been reported, almost all from East Asia (mainly Japan). Here we describe
 the first two c...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2500278</comments>
            <pubDate>Thu, 11 Jun 2009 14:12:45 +0100</pubDate>
            <guid isPermaLink="false">2500278</guid>        </item>
        <item>
            <title>Four novel PDHA1 mutations in pyruvate dehydrogenase deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2500279&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu065172g282371h2%2F</link>
            <description>This study adds four
 novel mutations to the around 90 reported mutations in PDHA1 (HGMD PDHA1 mutation database). The phenotypes of patients with PDH deficiency have been divided into three groups: a neonatal form with
 severe lactic acidosis, a form observed only in males and characterized by episodes of ataxia with relapses associated with
 hyperlactataemia, and an infantile form with hypotonia, lethargy, onset of seizures or dystonia, psychomotor retardation,
 in some cases Leigh-like lesions and mild to moderate hyperlactataemia. The four patients reported here all belong to the
 latter group, which is the largest.
 
	Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10545-009-1179-8Authors
		E. Ostergaard, Copenhagen University Hospital Rigshospitalet Department of Clinic...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2500279</comments>
            <pubDate>Thu, 11 Jun 2009 14:12:44 +0100</pubDate>
            <guid isPermaLink="false">2500279</guid>        </item>
        <item>
            <title>Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: Assessing responsiveness in a model of statistical process control</title>
            <link>http://www.medworm.com/index.php?rid=2500280&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq5362g3101261048%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Tetrahydrobiopterin (BH4) cofactor loading is a standard procedure to differentiate defects of BH4 metabolism from phenylalanine hydroxylase (PAH) deficiency. BH4 responsiveness also exists in PAH-deficient patients with high residual PAH activity. Unexpectedly, single cases with presumed
 nil residual PAH activity have been reported to be BH4 responsive, too. BH4 responsiveness has been defined either by a ≥30% reduction of blood Phe concentration after a single BH4 dose or by a decline greater than the individual circadian Phe level variation. Since both methods have methodological disadvantages,
 we present a model of statistical process control (SPC) to assess BH4 responsiveness. Phe levels in 17 adult PKU patients of three phenotypic groups off diet were compared ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2500280</comments>
            <pubDate>Wed, 10 Jun 2009 11:28:47 +0100</pubDate>
            <guid isPermaLink="false">2500280</guid>        </item>
        <item>
            <title>Coenzyme Q10 is decreased in fibroblasts of patients with methylmalonic aciduria but not in mevalonic aciduria</title>
            <link>http://www.medworm.com/index.php?rid=2467111&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhq222m76r1w2j576%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;The content of coenzyme Q10 (CoQ10) was examined in skin fibroblasts of 10 patients with mevalonic aciduria (MVA) and of 22 patients with methylmalonic aciduria
 (MMA). Patients with these inborn errors of metabolism are thought to be at risk for CoQ10 depletion either by direct inhibition of the proximal pathway of CoQ10 synthesis (MVA) or indirectly by inhibition of mitochondrial energy metabolism (MMA). We demonstrated that CoQ10 concentrations were not significantly different from controls in MVA patients, suggesting that there may be upregulatory
 effects. On the other hand the CoQ10 content in fibroblasts of patients with MMA was significantly reduced.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10545-009-1150-8Authors
		D. Haas, University...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2467111</comments>
            <pubDate>Sun, 07 Jun 2009 08:54:56 +0100</pubDate>
            <guid isPermaLink="false">2467111</guid>        </item>
        <item>
            <title>Black hip, fracture neck of femur and scoliosis: A case of ochronosis</title>
            <link>http://www.medworm.com/index.php?rid=2467112&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1688454727634x66%2F</link>
            <description>Conclusion: We report a case of scoliosis, fracture of the neck of the femur and ochronosis occurring together in a patient.
 
	Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10545-009-1172-2Authors
		B. Zacharia, Government Medical College Calicut IndiaJ. Chundarathil, Government Medical College Thrissur IndiaV. Ramakrishnan, Government Medical College Thrissur IndiaR. M. Krishnankutty, Government Medical College Calicut IndiaR. Veluthedath, Government Medical College Calicut IndiaK. Puthezhath, Government Medical College Calicut IndiaI. Varughese, Government Medical College Calicut India
	

	
		Journal Journal of Inherited Metabolic DiseaseOnline ISSN 1573-2665Print ISSN 0141-8955 (Source: Journal of Inherited Metabolic Disease)</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2467112</comments>
            <pubDate>Sun, 07 Jun 2009 08:54:55 +0100</pubDate>
            <guid isPermaLink="false">2467112</guid>        </item>
        <item>
            <title>Can we use statins to prevent stroke in Fabry disease?</title>
            <link>http://www.medworm.com/index.php?rid=2462350&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw2858g7r28ux8x4q%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Fabry disease is a rare, X-linked lysosomal storage disease caused by an inborn deficiency of α-galactosidase A, which results
 in the progressive accumulation of globotriaosylceramide and other neutral glycolipids in a range of cells and tissues. In
 association with the renal and cardiac insufficiency, cerebrovascular complications can result in the death of the patients.
 Several mechanisms causing vascular damage that leads to the development of deep-white matter lesions have been described.
 Recent clinical trials strongly suggest that statins protect against stroke by neuroprotective properties or pleiotropic effects.
 Aim: To evaluate evidence and potential beneficial effects of statins in the vasculopathy of Fabry disease.
 
	Content Type Journal ArticleCategory...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2462350</comments>
            <pubDate>Thu, 04 Jun 2009 10:00:54 +0100</pubDate>
            <guid isPermaLink="false">2462350</guid>        </item>
        <item>
            <title>Visual evoked potentials in succinate semialdehyde dehydrogenase (SSADH) deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2454355&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe120237346417714%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;In mammals, increased GABA in the central nervous system has been associated with abnormalities of visual evoked potentials
 (VEPs), predominantly manifested as increased latency of the major positive component P100. Accordingly, we hypothesized that
 patients with a defect in GABA metabolism, succinate semialdehyde dehydrogenase (SSADH) deficiency (in whom supraphysiological
 levels of GABA accumulate), would manifest VEP anomalies. We evaluated VEPs on two patients with confirmed SSADH deficiency.
 Whereas the P100 latencies and amplitudes for binocular VEP analyses were within normal ranges for both patients, the P100
 latencies were markedly delayed for left eye (OS) (and right eye (OD), patient 1) and monocular OS (patient 2): 134–147&amp;nbsp;ms;
 normal &amp;lt;118&amp;nbsp...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2454355</comments>
            <pubDate>Sat, 30 May 2009 08:06:53 +0100</pubDate>
            <guid isPermaLink="false">2454355</guid>        </item>
        <item>
            <title>Cognitive, behavioural and adaptive profiles of children with glutaric aciduria type I detected through newborn screening</title>
            <link>http://www.medworm.com/index.php?rid=2435736&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F850582637240l1n7%2F</link>
            <description>Conclusions: These findings highlight the importance of in-depth assessments of all aspects of neuropsychological function in patients
 with GA I and provide a basis for future neuropsychological assessment in similar groups of children. In spite of relatively
 preserved overall functioning, using a broad range of sensitive cognitive and motor measures facilitates the detection of
 subtle deficits, and allows for planning of early and adequate therapeutic interventions.
 
	Content Type Journal ArticleCategory Short ReportDOI 10.1007/s10545-009-1167-zAuthors
		M. H. Beauchamp, Australian Centre for Child Neuropsychological Studies Murdoch Children’s Research Institute Melbourne AustraliaA. Boneh, Royal Children’s Hospital Metabolic Service, Genetic Health Services Victoria, Murdoch Chil...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2435736</comments>
            <pubDate>Sun, 24 May 2009 06:14:49 +0100</pubDate>
            <guid isPermaLink="false">2435736</guid>        </item>
        <item>
            <title>Chitotriosidase plasma activity in nephropathic cystinosis</title>
            <link>http://www.medworm.com/index.php?rid=2431404&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj81354702471k42g%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Chitotriosidase is a fully active chitinase produced and secreted by activated phagocytes. Plasma chitotriosidase activity
 is a well-established marker of total disease burden in Gaucher disease that has proved useful in monitoring the response
 to both enzyme replacement and substrate reduction therapies in patients with Gaucher disease. Increased chitrotriosidase
 plasma activity has also been observed in several other lysosomal and non lysosomal disorders. Cystinosis, a rare multisystemic
 lysosomal storage disease, is characterized by the intralysosomal accumulation of free cystine in many cell types including
 phagocytes. We here report on plasma chitotriosidase activity in a child with nephropathic cystinosis. Increased plasma chitotriosidase
 activity (481nmol/h ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2431404</comments>
            <pubDate>Wed, 20 May 2009 06:17:41 +0100</pubDate>
            <guid isPermaLink="false">2431404</guid>        </item>
        <item>
            <title>Neuroimaging findings in children with paediatric neurotransmitter diseases</title>
            <link>http://www.medworm.com/index.php?rid=2431403&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj35336468k0u2834%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Paediatric neurotransmitter diseases consist of a group of inherited neurometabolic diseases in children, and include disorders
 related to γ-amino butyric acid (GABA) metabolism, monoamine biosynthesis, etc. The diagnosis of paediatric neurotransmitter
 diseases remain a great challenge for paediatricians and child neurologists. In addition to clinical manifestations and CSF
 neurotransmitter measurement, neuroimaging findings can also be very informative for the diagnosis and evaluation of the patients.
 For patients with monoamine biosynthesis disorders, the functional evaluation of dopaminergic transmission also plays an important
 role. Understanding of the possible neuroimaging changes in paediatric neurotransmitter diseases is therefore of great value
 for the in...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2431403</comments>
            <pubDate>Wed, 20 May 2009 06:17:41 +0100</pubDate>
            <guid isPermaLink="false">2431403</guid>        </item>
        <item>
            <title>Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop</title>
            <link>http://www.medworm.com/index.php?rid=2426411&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0773w511v63765r4%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;Published data on treatment of fatty acid oxidation defects are scarce. Treatment recommendations have been developed on the
 basis of observations in 75 patients with long-chain fatty acid oxidation defects from 18 metabolic centres in Central Europe.
 Recommendations are based on expert practice and are suggested to be the basis for further multicentre prospective studies
 and the development of approved treatment guidelines. Considering that disease complications and prognosis differ between
 different disorders of long-chain fatty acid oxidation and also depend on the severity of the underlying enzyme deficiency,
 treatment recommendations have to be disease-specific and depend on individual disease severity. Disorders of the mitochondrial
 trifunctional protein are ...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2426411</comments>
            <pubDate>Tue, 19 May 2009 06:01:55 +0100</pubDate>
            <guid isPermaLink="false">2426411</guid>        </item>
        <item>
            <title>Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders</title>
            <link>http://www.medworm.com/index.php?rid=2421697&amp;cid=s_35991_49_f&amp;fid=35991&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa822242236r18221%2F</link>
            <description>We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter
 diseases.
 
	Content Type Journal ArticleCategory SYMPOSIUM ON NEUROTRANSMITTER DISORDERSDOI 10.1007/s10545-009-1190-0Authors
		S. Evans, The George Washington University School of Medicine Department of Physiatry, Childrens National Medical Center 111 Michigan Avenue, NW Washington DC 20010 USAK. Forester, The George Washington University School of Medicine Department of Neurology, Childrens National Medical Center Washington DC USAJ. M. Pettiford, The George Washington University School of Medicine Department of Neurology, Childrens National Medical Center Washington DC USAO. Morozova, The George Washington University School of Medicine Department of Physiatry, Childr...</description>
            <author>Journal of Inherited Metabolic Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2421697</comments>
            <pubDate>Sun, 17 May 2009 06:46:23 +0100</pubDate>
            <guid isPermaLink="false">2421697</guid>        </item>
    </channel>
</rss>
